0001356090-23-000004 | 10-K | XBRL Viewer

Short-term and Long-term Investments

12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2022:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Aggregate Fair Value
United States government debt securities	$	51,755	$	—	$	(760)	$	50,995
Certificates of deposit	97		—		—		97
Total	$	51,852	$	—	$	(760)	$	51,092

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Aggregate Fair Value
United States government debt securities	$	121,036	$	—	$	(331)	$	120,705
Certificates of deposit	97		—		—		97
Total	$	121,133	$	—	$	(331)	$	120,802

See Notes 2 and 7 for further discussion on the Company's method for determining the fair value of its assets.

The estimated fair value of available-for-sale investments classified by their contractual maturities as of December 31, 2022 was:


Due within one year	$	51,092
After one year through two years	—
Total	$	51,092

Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments.

Operating Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Operating Leases

The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of less than one year to eight years, some of which may include options to extend the lease and some of which may include options to terminate the lease within one year. The Company uses judgment to determine whether it is reasonably possible to extend the lease beyond the initial term or terminate before the initial term ends and the length of the possible extension or early termination. The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions.

The components of lease costs were as follows:


	Year Ended December 31,
	2022		2021		2020
Operating lease costs	$	2,444	$	2,872	$	3,239
Short-term lease costs	170		252		311
Variable lease costs	422		800		842
Lease costs	$	3,036	$	3,924	$	4,392

As of December 31, 2022, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:


2023	$	2,074
2024	1,882
2025	1,851
2026	1,508
2027	1,246
Thereafter	3,108
Total	11,669
Present value adjustment	(3,468)
Total	$	8,201
Current portion of operating lease liabilities	$	1,209
Long-term portion of operating lease liabilities	6,992
Total	$	8,201

Other information related to operating leases in continuing operations was as follows:


	December 31,
	2022		2021
Weighted average remaining lease term (years)	6.09		6.72
Weighted average discount rate	11.05	%	10.94	%


	Year Ended December 31,
	2022		2021		2020
Supplemental disclosure of cash flow information
Cash paid for operating lease liabilities	$	2,493	$	3,199	$	3,679
Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases)	466		4,868		112

During the year ended December 31, 2022, 2021 and 2020 the company recorded impairment charges related to right-of-use assets. See Note 9 for further discussion.

Collaboration and Licensing Revenue

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration and Licensing Revenue

The Company's collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.

The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation.

The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2022, 2021, and 2020.


	Year Ended December 31,
	2022		2021		2020
Alaunos Therapeutics, Inc.	$	100	$	100	$	200
Oragenics, Inc.	—		—		3,053
Intrexon Energy Partners, LLC	3,768		—		—
Intrexon Energy Partners II, LLC	10,793		—		—
Castle Creek Biosciences, Inc.	—		388		17,810

Other	—		18		145
Total (1)	$	14,661	$	506	$	21,208

(1)Collaboration and licensing revenues recognized for the years ended December 31, 2022, 2021, and 2020, include the recognition of $14,561, $397, and $20,205, respectively, associated with upfront and milestone payments which were previously deferred.

The following is a summary of the terms of the Company's significant collaborations and licensing agreements from continuing operations.

Intrexon Energy Partners and Intrexon Energy Partners II Collaborations

In July 2022, the Company obtained control of both of Intrexon Energy Partners Board and Intrexon Energy Partners II Board (as discussed in Notes 3, and 4). Based on its assessment of the status of each collaboration and ultimate dissolution of Intrexon Energy Partners and Intrexon Energy Partners II, the Company determined that it was probable that no further performance obligations would occur under the respective collaboration agreements. Accordingly, the Company recognized the remaining balance of deferred revenue associated with Intrexon Energy Partners and Intrexon Energy Partners II, less the amounts paid to acquire the membership interests of the investors of $7,000, for an aggregate amount of revenue recognized of approximately $14,561.

Alaunos Collaborations

In 2018, the Company, through its wholly owned subsidiary PGEN Therapeutics, entered into a license agreement (the "Alaunos License Agreement") with Alaunos Therapeutics, Inc., formerly known as ZIOPHARM Oncology, Inc. ("Alaunos"), which terminated and replaced the terms of the ECC agreement entered into between the Company and Alaunos in 2011, including the amendments thereto. Contemporaneously with the execution of the license agreement, Alaunos ceased to be a related party. Pursuant to the terms of the Alaunos License Agreement, the Company granted Alaunos an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i) products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii) chimeric antigen receptor ("CAR") products directed to (a) CD19 for the treatment of cancer (the "CD19 Products"), and (b) a second target, subject to certain rights as discussed in the agreement, and (iii) T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted Alaunos an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's Sleeping Beauty technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of cancer and in the HPV Field. Alaunos will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. Alaunos is required to use commercially reasonable efforts to develop and commercialize IL-12 Products, CD19 Products, and the TCR Products. The Company also granted Alaunos an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. Alaunos is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. Alaunos and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with Alaunos responsible for 80% of the development costs and receiving 80% of the operating profits, as defined in the Alaunos License Agreement, and the Company responsible for the remaining 20% of the development costs and receiving 20% of the operating profits, except that Alaunos will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program").

Under the Alaunos License Agreement, Alaunos will pay the Company an annual license fee of $100 and, in 2019, reimbursed the Company $1,000 with respect to historical Gorilla IL-12 Products. Alaunos will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed programs in various jurisdictions, totaling up to an additional $52,500 for each of four exclusively licensed programs, up to an aggregate of $210,000. In addition, Alaunos will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. Alaunos will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $100,000 in the aggregate. Alaunos will also pay the Company 20% of any sublicensing income received by Alaunos relating to the licensed products.

Under the Alaunos License Agreement, the Company reacquired rights previously held by Alaunos to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to Alaunos. The Company will pay Alaunos royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $50,000. The Company also received from Alaunos reimbursement of costs incurred to transition the necessary knowledge and materials for Alaunos programs for a period of one year from the effective date (the "Transition Services").

The Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to Alaunos for such products. The Alaunos License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of the later to occur of (i) the expiration of the last to expire patent claim for a licensed product, or (ii) 12 years after the first commercial sale of a licensed product in such country. In addition, Alaunos may terminate the Alaunos License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the Alaunos License Agreement following notice of a material breach.

Replacement of the original ECC with the Alaunos License Agreement was a contract modification under ASC 606 that represented the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which were limited to the Transition Services, were distinct from those under the ECC. The Company determined the new agreement had a transaction price of $1,855, the majority of which related to a portion of the deferred revenue remaining from the original ECC. The annual license payments, excluding the first such payment which was included in the transaction price, and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being received. Royalty payments from sales of Alaunos products developed pursuant to the Alaunos License Agreement will be recognized when the sales occur. The Company recognized payments from Transition Services as those services were performed and recognized the transaction price as it performed the Transition Services required under the Alaunos License Agreement.

The Company determined that the Gorilla Program represented a separate collaboration agreement under the scope of ASC 808, Collaborative Arrangements, ("ASC 808") and was not included in the accounting for the Alaunos License Agreement under ASC 606. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808.

Oragenics Collaboration

In 2015, the Company entered into an ECC with Oragenics, a related party at the time. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of the ECC, the Company received a technology access fee of a $5,000 convertible promissory note, which was subsequently converted to shares of Oragenics' common stock. These shares were sold in the TS Biotechnology Sale in 2020 (Note 3). The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. In July 2020, the Company and Oragenics mutually agreed to terminate the ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the ECC totaling $2,823. Following the termination of the ECC, Oragenics is no longer a related party.

Exotech Bio, AD Skincare, and Thrive Agrobiotics Collaborations

In 2015 and 2016, the Company entered into three separate ECCs with Exotech Bio, Inc. ("Exotech Bio"), AD Skincare, Inc. ("AD Skincare"), and Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), all affiliates of Harvest and related parties at the time. The total upfront consideration received for the three collaborations was $11,000, which consisted of equity interests in each of these entities. The Company also received reimbursements for research and development services provided pursuant to the

ECCs. In conjunction with a settlement agreement with Harvest (Note 17), these ECCs were terminated in December 2020, and the previously licensed technology rights reverted to the Company pursuant to the ECCs. The Company wrote off the remaining balance of deferred revenue associated with these ECCs in 2020 totaling $6,993 as an offset to the loss recognized on the settlement agreement.

Castle Creek Collaborations

In October 2012, the Company entered into an ECC (the "2012 Castle Creek ECC") with Castle Creek Biosciences, Inc. ("Castle Creek", formerly known as Fibrocell Science, Inc.). Castle Creek was a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until it was acquired in December 2019 by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek Pharmaceutical"), a privately held company focused on developing medicine for rare genetic disorders. Pursuant to the 2012 Castle Creek ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. The Company received (i) upfront consideration upon execution of the ECC in the form of Castle Creek common stock valued at $7,576, (ii) shares of Castle Creek common stock valued at $7,612 as consideration for a 2013 amendment which expanded the field of use defined in the agreement, (iii) sublicensing fees totaling $3,750 in the form of cash in 2019, and (iv) reimbursements for research and development services performed during the ECC.

In March 2020, the Company and Castle Creek terminated the 2012 Castle Creek ECC by mutual agreement ("Termination Agreement") with the parties agreeing that the two drug product candidates pursuant to the ECC would be treated as "Retained Products" under the terms of the 2012 Castle Creek ECC. One of these product candidates is D-Fi (debcoemagene autoficel), formerly designated FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB. Castle Creek retains a license under the 2012 Castle Creek ECC to continue to develop and commercialize the Retained Products within the field of use of the 2012 Castle Creek ECC for so long as Castle Creek continues to pursue such development and commercialization. No further licenses to the Company's technology are provided to Castle Creek. On a quarterly basis, Castle Creek will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each Retained Product, as defined in the agreement. Additionally, the Termination Agreement provided for the Company to perform certain drug product manufacturing activities related to the Retained Products. The Termination Agreement was accounted for as a new contract, and the remaining deferred revenue from the 2012 Castle Creek ECC was recognized prospectively through 2021 as the manufacturing activities were performed.

In December 2015, the Company entered into a second ECC with Castle Creek (the "2015 Castle Creek ECC"). Pursuant to the ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. In February 2020, the Company and Castle Creek mutually agreed to terminate the 2015 Castle Creek ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the 2015 Castle Creek ECC totaling $10,000 in 2020.

Deferred Revenue

Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. The arrangements classified as long-term (of which $0 and $21,205 was related to agreements with Intrexon Energy Partners and Intrexon Energy Partners II as of December 31, 2022 and December 31, 2021, respectively ) are not active while the respective counterparties evaluate the status of the project and its desired future development activities since the Company cannot reasonably estimate the amount of service to be performed over the next year. Deferred revenue consisted of the following:


	December 31,
	2022		2021
Collaboration and licensing agreements	$	1,818	$	23,023
Prepaid product and service revenues	15		1,277
Other	10		213
Total	$	1,843	$	24,513
Current portion of deferred revenue	$	25	$	1,490
Long-term portion of deferred revenue	1,818		23,023
Total	$	1,843	$	24,513

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Share-Based Payments - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	$ 10,206	$ 13,904	$ 18,366
Cost of products and services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	110	161	66
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	2,188	2,706	611
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	7,899	10,687	18,331
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	$ 9	$ 350	$ (642)

Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - Precigen Stock Option Plans - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Restricted Stock Units
Balances at beginning of period (in shares)	468,481	1,727,712	1,781,982
Granted (in shares)	1,387,831	462,019	3,157,390
Vested (in shares)	(1,125,785)	(1,624,013)	(2,802,593)
Forfeited (in shares)	(32,712)	(97,237)	(409,067)
Balances at period end (in shares)	697,815	468,481	1,727,712	1,781,982
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 8.47	$ 6.11	$ 8.71
Granted (in usd per share)	2.12	7.87	3.09
Vested (in usd per share)	(4.29)	(5.76)	(3.99)
Forfeited (in usd per share)	(7.26)	(8.96)	(8.59)
Balances at period end (in usd per share)	$ 2.66	$ 8.47	$ 6.11	$ 8.71
Additional Disclosures
Balances at period end, weighted average remaining contractual period	1 month 17 days	3 months 29 days	5 months 1 day	1 year 2 months 26 days

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Precigen, Inc. ("Precigen"), a Virginia corporation, through its wholly owned subsidiary, PGEN Therapeutics, Inc. (“PGEN Therapeutics”), is a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs. PGEN Therapeutics is leveraging its proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics has developed an extensive pipeline of therapies across multiple indications within these core focus areas. PGEN Therapeutics’ primary operations are located in Maryland. Precigen has two additional wholly owned operating subsidiaries. Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics, with its primary operations located in Ghent, Belgium. Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications. Exemplar’s primary operations are located in Iowa. Discontinued Operations On January 31, 2020, Precigen completed the sale of the majority of its non-healthcare assets and operations to an affiliate of Third Security, which are presented as discontinued operations for all periods presented. See Notes 3 and 13 for further discussion. Beginning in the second quarter of 2020, the Company suspended its proprietary methane bioconversion platform operations and began the process to wind down MBP Titan's activities and had substantially completed the wind down by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion. On August 18, 2022, Precigen completed the sale of 100% of the issued and outstanding membership interests in its wholly-owned subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), a provider of reproductive technologies, including services and products sold to cattle breeders and other producers. See Note 3 for further discussion. Trans Ova was formerly a separate reportable segment. Precigen and its consolidated subsidiaries are hereinafter collectively referred to as the "Company." Liquidity Management believes that existing liquid assets as of December 31, 2022, as well as the proceeds from the January 2023 public offering discussed in Note 13, will allow the Company to continue its operations for at least a year from the issuance date of these consolidated financial statements. These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of therapeutic product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development, and clinical manufacturing of its therapeutic product candidates. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2022, the Company incurred a loss from continuing operations of $79,777 and, as of December 31, 2022, had an accumulated deficit of $1,868,567. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its therapeutics product candidates, successfully commercialize its therapeutics product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations.

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 1,843	$ 24,513
Current portion of deferred revenue	25	1,490
Long-term portion of deferred revenue	1,818	23,023
Prepaid product and service revenues
Deferred Revenue Arrangement [Line Items]
Deferred revenue	15	1,277
Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	10	213
Collaboration and licensing agreements
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 1,818	$ 23,023

Share-Based Payments - Schedule of Stock Option Activity (Details) - Precigen Stock Option Plans - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Balances at beginning of period (in shares)	12,260,187	11,255,896	9,022,282
Granted (in shares)	4,451,890	2,058,820	5,693,498
Exercised (in shares)	(375)	(127,883)	(30,061)
Forfeited (in shares)	(567,179)	(305,293)	(976,324)
Expired (in shares)	(943,247)	(621,353)	(2,453,499)
Balances at period end (in shares)	15,201,276	12,260,187	11,255,896	9,022,282
Weighted Average Exercise Price (usd per share)
Balances at beginning of period (in usd per share)	$ 14.06	$ 15.53	$ 21.94
Granted (in usd per share)	2.22	7.59	10.03
Exercised (in usd per share)	(2.28)	(4.75)	(3.88)
Forfeited (in usd per share)	(5.19)	(7.02)	(15.47)
Expired (in usd per share)	(22.32)	(24.61)	(26.53)
Balances at period end (in usd per share)	$ 10.41	14.06	$ 15.53	$ 21.94
Additional Disclosures
Exercisable at period end (in shares)	8,559,359
Options exercisable, weighted average exercise price (in usd per share)	$ 13.58	$ 16.69
Balances at period end, weighted average remaining contractual period	6 years 10 months 13 days	6 years 9 months 14 days	7 years 3 months	6 years 1 month 6 days
Exercisable at period end, weighted average remaining contractual period	5 years 9 months

Shareholders' Equity - Additional Information (Details) - USD ($)			1 Months Ended			12 Months Ended
	Aug. 09, 2022	Jan. 31, 2020	Jan. 31, 2023	Jan. 31, 2021	Jul. 31, 2018	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares				17,250,000
Value of shares issued in public or private offering				$ 121,045,000		$ 121,045,000	$ 35,000,000
Shares issued in share lending agreement, shares					7,479,431
Share lending agreement, length of time for shares to be returned upon termination					5 days
Shares issued, price per share					$ 13.37
Maximum
Class of Stock [Line Items]
Sale of stock, consideration received on transaction	$ 100,000,000
Subsequent Event
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares			43,962,640
Value of shares issued in public or private offering			$ 73,000,000
TS Biotechnology Sale
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares		5,972,696
Value of shares issued in public or private offering		$ 35,000,000
Affiliated Entity \| Subsequent Event
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares			11,517,712

Discontinued Operations

12 Months Ended

Dec. 31, 2022

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Trans Ova

As part of the Company's strategic shift to becoming a primarily healthcare company, as discussed in Note 1, on August 18, 2022, the Company completed the sale of 100% of the issued and outstanding membership interests in its wholly-owned subsidiary,Trans Ova, to Spring Bidco LLC, a Delaware limited liability company for $170,000 and up to $10,000 in cash earn-out payments contingent upon the performance of Trans Ova in each of 2022 and 2023, $5,000 for each year (the “Transaction”). The Company received $162,306 in proceeds, net of certain transaction costs, on August 18, 2022, after giving effect to the preliminary closing purchase price adjustments. The final working capital adjustment of $936 was received in the fourth quarter of 2022. In February 2023, Spring Bidco LLC notified the company that Trans Ova did not meet the financial measures required in 2022 in order to require the first $5,000 earn-out payment. The Company has until March 15, 2023 to respond to Spring Bidco LLC.

The Company elected to account for the contingent consideration arrangement as a gain contingency in accordance with ASC 450, Contingencies (Subtopic 450-30). Under this approach, the Company recognizes the contingent consideration receivable in earnings after the contingency is resolved. Accordingly, to determine the initial gain on the sale of Trans Ova, the Company did not include an amount related to the contingent consideration arrangement as part of the consideration received.

In connection with the Transaction, the Company, as of December 31, 2022, holds restricted cash of $43,339, in a segregated account to be used for certain permitted purposes, including resolution of the Company’s outstanding convertible notes as discussed further in Note 11. In addition, the Company is required to indemnify the Buyer for certain expenses incurred post close (related to covenants and certain additional specified liabilities including certain patent infringement lawsuits), if incurred, in amounts not to exceed $5,750, which was recorded as a reduction of the gain on divestiture in the twelve months ended December 31, 2022, and is included in other accrued liabilities as of December 31, 2022. To date, the Company has not received an indemnification claim.

The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale related to Trans Ova as of December 31, 2021 are as follows:


	December 31,
	2021

Assets
Cash and cash equivalents	$	6,497
Trade Receivables, net	19,491
Inventory	12,935
Other current assets	1,265
Property, plan and equipment, net	25,716
Intangible assets, net	1,824
Goodwill	16,594
Right-of-use assets	910
Other noncurrent assets	252
Total assets held for sale	$	85,484
Liabilities
Accounts payable	$	2,293
Accrued compensation and benefits	3,367
Other accrued liabilities	3,778
Deferred revenue	2,952

Current portion of long-term debt	350
Other current liabilities	111
Long-term debt, net of current portion	2,867

Other long-term liabilities	805
Total liabilities held for sale or abandonment	$	16,523

The following table presents the financial results of discontinued operations related to TransOva through the date of disposition in 2022:


	Year Ended December 31,
	2022		2021		2020
Product revenues	$	21,494	$	25,131	$	21,914
Service revenues	49,657		64,475		49,272
Total revenues	71,151		89,606		71,186
Cost of products	18,634		23,070		26,529
Cost of services	22,701		29,570		23,610
Research and development	2,348		2,208		2,216
Selling, general and administrative	15,215		22,128		19,010
Impairment of assets	—		—		106
Total operating expenses	58,898		76,976		71,471
Operating income (loss)	12,253		12,630		(285)
Other income, net	1,139		1,412		1,489
Equity in net loss of affiliates	—		—		(535)
Gain on divestiture	94,702		—		—
Income before income taxes	$	108,094	$	14,042	$	669
Income tax (expense) benefit	—		—		—
Income from discontinued operations	$	108,094	$	14,042	$	669

The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to Trans Ova that are included in the accompanying consolidated statements of cash flows:


	Year Ended December 31,
	2022	2021	2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	3,574	5,622	6,750

Impairment of assets	—	—	106
Loss on disposal of assets	421	561	4,325
Equity in net loss of affiliates	—	—	535


Provision for credit losses	944	1,128	899
Stock-based compensation expense	9	350	738


Cash flows from investing activities
Proceeds from repayment of notes receivable	—	3,689	—
Purchases of property, plant and equipment	(3,529)	(4,694)	(6,365)
Proceeds from sales of assets	594	1,894	2,387

MBP Titan

As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially completed by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. This discontinuation of operations represented the continuation of a strategic shift to becoming primarily a healthcare company advancing technologies and products that address complex healthcare challenges that the Company commenced as part of the Transactions defined and discussed below. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are classified and presented as discontinued operations in the accompanying consolidated financial statements for all periods.

The January 2021 sale of property and equipment resulted in a gain on disposal of assets of $464, which is included in income from discontinued operations in the accompanying consolidated statement of operations for the year ended December 31, 2021. In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility that were originally due to expire in July 2025. This lease termination resulted in a gain of $4,602, which is also included in income from discontinued operations in the accompanying consolidated statement of operations for the year ended December 31, 2021.

After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners, LLC ("Intrexon Energy Partners") and Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), including the associated deferred revenue remaining under each collaboration agreement (Notes 4 and 5), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying consolidated financial statements for all periods presented as a result of the Company's continuing involvement.

The following table presents the financial results of discontinued operations related to MBP Titan:


	Year Ended December 31,
		2021		2020

Operating (gains) expenses (1)		$	(4,599)	$	40,692
Operating income (loss)		4,599		(40,692)




Income (loss) before income taxes		4,599		(40,692)

Income (loss) from discontinued operations		$	4,599	$	(40,692)

(1)Includes an impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.

The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan that are included in the accompanying consolidated statements of cash flows.


	Year Ended December 31,
	2021		2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	—	2,474
Impairment of goodwill	—		9,635
Impairment of other noncurrent assets	—		12,406
(Gain) loss on disposal of assets, net	(464)		67




Stock-based compensation expense	—		(34)

Noncash gain on termination of leases	(4,602)		—
Cash flows from investing activities

Purchases of property, plant and equipment	—		(88)
Proceeds from sales of assets	1,083		3,952

Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc.

On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's non-healthcare assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities that were directly related to the subsidiaries sold:

•Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc.;

•Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which focused on biological insect solutions;

•ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds; and

•Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations that were previously an operating division within Precigen.

Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions".

Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $26,957 were released to earnings and included in loss from discontinued operations. See further discussion below regarding this out-of-period adjustment.

The transactions were approved by the Company's independent members of the board of directors in December 2019.

The following tables present the financial results of discontinued operations related to the Transactions for the year ended December 31, 2020.


	Year Ended December 31, 2020
	TS Biotechnology Sale		EnviroFlight Sale		Total
Revenues (1)	$	1,294	$	—	$	1,294
Operating expenses	896		—		896
Operating income	398		—		398
Gain on sale of discontinued operations	633		39		672
Loss on release of cumulative foreign currency translation adjustment	(26,957)		—		(26,957)
Other expense, net	(129)		—		(129)
Equity in net loss of affiliates	—		(38)		(38)
Income (loss) before income taxes	(26,055)		1		(26,054)
Income tax expense	(2)		—		(2)
Income (loss) from discontinued operations	$	(26,057)	$	1	$	(26,056)

(1)Includes revenue recognized from related parties of $436.

The following table presents the significant noncash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.


	Year Ended December 31,
	2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	—
Impairment of goodwill	—
Impairment of other noncurrent assets	—
Gain on sale of discontinued operations	(672)
Loss on release of cumulative foreign currency translation adjustment	26,957
Unrealized and realized depreciation on equity securities and preferred stock, net	106
Equity in net loss of EnviroFlight	38
Stock-based compensation expense	(1,346)
Deferred income taxes	—
Cash flows from investing activities
Investments in EnviroFlight	—
Purchases of property, plant and equipment	(382)

Equity Method Investments

The Company accounted for its investment in EnviroFlight using the equity method of accounting.

Summarized financial data for EnviroFlight for the periods in which the Company held the equity method investment were not material.

Out-of-Period Adjustment

During the year ended December 31, 2020, the Company recorded an out-of-period adjustment of $26,572 to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Sale. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Sale nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's results of operations for the year ended December 31, 2020.

Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustment		$ 0	$ 0	$ (26,957)
TS Biotechnology Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues				1,294
Operating expenses				896
Operating income (loss)				398
Gain on sale of discontinued operations				633
Loss on release of cumulative foreign currency translation adjustment	$ (26,957)			(26,957)
Other expense, net				(129)
Equity in net loss of affiliates				0
Income (loss) before income taxes				(26,055)
Income tax expense				(2)
Income (loss) from discontinued operations				(26,057)
TS Biotechnology Sale \| Discontinued Operations, Disposed of by Sale \| Related Parties, Aggregated
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues				436
EnviroFlight Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues				0
Operating expenses				0
Operating income (loss)				0
Gain on sale of discontinued operations				39
Loss on release of cumulative foreign currency translation adjustment				0
Other expense, net				0
Equity in net loss of affiliates				(38)
Income (loss) before income taxes				1
Income tax expense				0
Income (loss) from discontinued operations				1
TS Biotechnology Holdings, LLC and EnviroFlight, LLC \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues				1,294
Operating expenses				896
Operating income (loss)				398
Gain on sale of discontinued operations				672
Loss on release of cumulative foreign currency translation adjustment				(26,957)
Other expense, net				(129)
Equity in net loss of affiliates				(38)
Income (loss) before income taxes				(26,054)
Income tax expense				(2)
Income (loss) from discontinued operations				$ (26,056)

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies In October 2020, several shareholder class action lawsuits were filed in the United States District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiffs' claims challenged disclosures about the MBP program from May 10, 2017 to March 1, 2019. In March 2021, the court granted an order consolidating the claims and, in April 2021, appointed a lead plaintiff and lead counsel in the case, captioned In re Precigen Securities Litigation, Case No. 5:20-cv-06936-BLF (N.D. Cal.). On May 18, 2021, the lead plaintiff filed an Amended Class Action Complaint. On August 2, 2021, the defendants moved to dismiss the Amended Class Action Complaint. On September 27, 2021, the lead plaintiff filed a Second Amended Class Action Complaint in lieu of a response to the defendants’ motion to dismiss. On November 3, 2021, the defendants moved to dismiss the Second Amended Class Action Complaint and on May 31, 2022, the court granted the defendants’ motion to dismiss the Second Amended Class Action Complaint with leave to amend. On August 1, 2022, the lead plaintiff filed a Third Amended Class Action Complaint. On August 2, 2022 the Court granted the parties' request to conduct a private mediation session to explore potential resolution of the action. On November 17, 2022, at the conclusion of the mediation session, the parties executed a memorandum of understanding that agreed in principle to resolve the claims asserted in the securities class action. The settlement provides for a payment to the plaintiff class of $13,000. The proposed settlement requires final negotiation of the terms of settlement and both preliminary and final approval by the court. Should the court not approve the proposed settlement or if the proposed settlement otherwise does not become final, the parties will be returned to their litigation postures prior to the agreement in principle to settle. In the event that the litigation resumes, the defendants intend to move to dismiss the plaintiff’s Third Amended Class Action Complaint. During the quarter ended December 31, 2022, we recorded an accrual of $13,000 in Other accrued liabilities and separately recognized an insurance receivable asset of $12,411 within Receivables, other, on the consolidated balance sheet, in addition to expense of $589 recorded in selling, general and administrative on the consolidated statement of operations, the amount remaining on its self-insured retention/deductible. In December 2020, a derivative shareholder action, captioned Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al, was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. asserting similar claims under state law against Precigen's current directors and certain officers. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The case was stayed by an order entered on June 14, 2021. On September 24, 2021, an individual shareholder filed a lawsuit in the Circuit Court for Henrico County styled Kent v. Precigen, Inc., Case CL21-6349. The Kent action demands inspection of certain books and records of the Company pursuant to Virginia statutory and common law. On April 1, 2022, the court denied the demurrer and referred the matter to a hearing on the merits. The Company intends to defend the lawsuits vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits. In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters may result in adverse judgments, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company’s business or operations. Moreover, such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2022, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for Credit Losses
Charged to operating expenses	$ 944	$ 1,268	$ 899
Continuing Operations
Allowance for Credit Losses
Beginning balance	1,693	1,509	2,312
Charged to operating expenses	0	140	0
Write offs of accounts receivable, net of recoveries	(1,509)	44	(803)
Ending balance	$ 184	$ 1,693	$ 1,509

Lines of Credit and Long-Term Debt

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Lines of Credit and Long-Term Debt

Lines of Credit

Exemplar has a $2,500 revolving line of credit with American State Bank that matures on October 31, 2023. As of December 31, 2022, the line of credit bore interest at 7.00% per annum. As of December 31, 2022 and December 31, 2021, there was no outstanding balance.

Long-Term Debt

Long-term debt consists of the following:


	December 31,
	2022		2021
Convertible debt	$	43,219	$	179,882

Other	—		52
Long-term debt	43,219		179,934
Less current portion	43,219		52
Long-term debt, less current portion	$	—	$	179,882

Convertible Debt

Precigen Convertible Notes

In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042.

The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at

Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances:

•During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

•During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or

•Upon the occurrence of specified corporate events as defined in the Indenture.

None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December 31, 2022. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. The Convertible Notes do not allow Precigen to call the debt prior to the maturity date.

If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture.

The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount.

As described in Note 2, the Company adopted ASU 2020-06 on January 1, 2022. Pursuant to ASU 2020-06, the equity components of the Convertible Notes separated from the debt components as required under the cash conversion model is required to be recombined into the Convertible Notes as a single instrument upon the adoption of ASU 2020-06. The Convertible Notes shall be accounted for as if the conversion option had not been separated. As the Company elected the modified retrospective approach, the difference between the accounting under the cash conversion model and new model after the adoption of ASU 2020-06 (i.e., the single debt instrument with no separation) was recorded as an adjustment on the adoption date (i.e., January 1, 2022) through accumulated deficit. Tax accounting consequences of the adoption also required the reversal of the previously reported deferred tax benefit on the date of adoption through accumulated deficit.

Adoption of ASU 2020-06 resulted in an increase to long-term debt outstanding, net of current portion, of $18,196, a decrease to additional paid-in capital of $36,868, and a decrease to accumulated deficit of $18,672. Interest expense recognized on the convertible notes in future periods was expected to be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.

As discussed in Note 3, in connection with the sale of Trans Ova in 2022, the Company transferred a total of $200,000 into a segregated account to be used for certain permitted purposes, including resolution of the Company's outstanding Convertibles Notes. During the year December 31, 2022 and subsequently, the Company executed open market purchases of a portion of the outstanding Convertible Notes. During the year ended December 31, 2022, the Company retired $156,660 of principal balance

from these purchases and recorded a gain on extinguishment of debt of approximately $961, which was recorded within Other income (expense), net, within the consolidated statements of operations. As of December 31, 2022, $43,339 of restricted cash remained in the segregated account noted above for permitted purposes including the resolution of the Company's outstanding Convertible Notes.

As of December 31, 2022, the outstanding principal balance on the Convertible Notes was $43,340 and their carrying value was $43,219. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 4.25%. As of December 31, 2022, the unamortized debt discount and debt issuance costs related to the Convertible Notes totaled $121.

Subsequent to year-end, the Company repurchased an additional $15,460 of principal balance of Convertible Notes at a price of $15,305, using restricted cash for the purchase.

The components of interest expense related to the Convertible Notes were as follows:


	Year Ended December 31,
	2022		2021		2020
Cash interest expense	$	5,727	$	7,000	$	7,000
Non-cash interest expense	1,042		11,735		10,587
Total interest expense	$	6,769	$	18,735	$	17,587

Accrued interest of $759 is included in other accrued liabilities on the accompanying consolidated balance sheet as of December 31, 2022.

See Note 2 for additional discussion regarding the Convertible Notes.

ActoBio Convertible Notes

In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest. The ActoBio Notes, which accrued interest at 3.0% compounded annually ("accrued PIK interest"), matured in September 2020. The Company issued 6,293,402 shares of Precigen common stock upon conversion of the outstanding principal balance and accrued PIK interest at maturity. Interest expense was $616 for the year ended December 31, 2020.

Future Maturities

Future maturities of long-term debt as of December 31, 2022 are as follows:


2023	$	43,340
2024	—
2025	—
2026	—
2027	—
Thereafter	—
Total	$	43,340

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Revenues	$ 26,909	$ 14,267	$ 31,992
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	14,661	506	21,208
Continuing Operations
Related Party Transaction [Line Items]
Revenues	26,909	14,267	31,992
Continuing Operations \| Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	14,661	506	21,208
Continuing Operations \| Collaboration and licensing agreements \| Related Parties, Aggregated
Related Party Transaction [Line Items]
Revenues	$ 14,561	$ 0	$ 3,053

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Credit Facility - Exemplar Genetics, LLC - American State Bank - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 2,500,000
Debt instrument, interest rate, stated percentage	7.00%
Line of credit outstanding	$ 0	$ 0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 4,773
2024	4,773
2025	4,773
2026	4,773
2027	4,773
Thereafter	20,590
Finite-lived intangible assets, net, total	$ 44,455	$ 52,291

Shareholders' Equity

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Shareholders' Equity

Issuances of Precigen Common Stock

In January 2021, the Company closed a public offering of 17,250,000 shares of its common stock, resulting in net proceeds of $121,045, after deducting underwriting discounts and capitalizable offering expenses.

Concurrent with entering into the TS Biotechnology Sale on January 1, 2020 (Note 3), the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020.

In January 2023, the Company closed a public offering of 43,962,640 shares of its common stock, resulting in net proceeds of approximately $73,000, after deducting underwriting discounts, fees, and other underwriting expenses. Of the 43,962,640 shares issued, 11,517,712 shares were purchased by related parties and their affiliates.

See Notes 11 and 17 for discussion regarding additional issuances of Precigen common stock.

Share Lending Agreement

Concurrently with the offering of the Convertible Notes (Note 11), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within five business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Share Borrower maintains collateral in the form of cash or certain permitted non-cash collateral with a market value at least equal to the market value of the Borrowed Shares as security for the obligation of the Share Borrower to return the Borrowed Shares when required by the terms above. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Precigen did not receive any proceeds from the sale of the Borrowed Shares to the public or any lending fees from the Share Lending Agreement. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering.

The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement.

At-the-Market Sales Agreement

On August 9, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may issue and sell from time to time shares of the Company’s common stock, no par value per share (the “Shares”), through the Agent. The offering and sale of up to $100,000 of the Shares has been registered under the Securities Act of 1933. The Company has no obligation to sell any of the Shares under the Sales Agreement, and may at any time suspend or terminate the offering of its common stock pursuant to the Sales Agreement upon notice and subject to other conditions. The Company intends to use the proceeds of any sales to fund the development of clinical and preclinical product candidates and for working capital and other general corporate purposes.

No shares were sold in connection with the Sales Agreement during the year ended December 31, 2022.

Components of Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive income (loss) are as follows:


	December 31,
	2022		2021
Unrealized gain (loss) on investments	$	(760)	$	(331)
Income (loss) on foreign currency translation adjustments	(2,728)		534
Total accumulated other comprehensive income (loss)	$	(3,488)	$	203

See Note 3 for further discussion of the release of cumulative losses on foreign currency translation adjustments upon the closing of the TS Biotechnology Sale.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2018
Organization And Significant Accounting Policies [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
Research and development commitments with third parties not incurred	$ 19,909	$ 22,301
Maturity period of highly liquid investment	3 months
Cash equivalent investments in highly liquid money market accounts	$ 2,985	20,697
Restricted cash	$ 43,339	$ 0
Antidilutive securities excluded from computation of earnings per share, amount	15,899,091	12,850,556	13,116,872
Long-term debt, net of current portion	$ 0	$ 179,882
Additional paid-in capital	1,998,314	2,022,701
Accumulated deficit	(1,868,567)	$ (1,915,556)
Non-cash interest expense	$ 11,800
Convertible debt
Organization And Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,542,420	11,732,440	11,732,440
3.5% Convertible Notes Due 2023
Organization And Significant Accounting Policies [Line Items]
Conversion price (in usd per share)	$ 17.05			$ 17.05
Non-cash interest expense	$ 1,042	$ 11,735	$ 10,587
Cumulative effect of adoption of ASU 2020-06
Organization And Significant Accounting Policies [Line Items]
Long-term debt, net of current portion		18,196
Additional paid-in capital		(36,868)
Accumulated deficit		$ 18,672
Minimum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset	3 years
Maximum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset	18 years
Precigen Stock Option Plans
Organization And Significant Accounting Policies [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Products and services revenues
Organization And Significant Accounting Policies [Line Items]
Product and service revenues, standard payment terms	30 days

Fair Value Measurements - Additional Information (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Jul. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of convertible debt	$ 43,000	$ 160,000
Carrying value of convertible debt	$ 43,219	$ 179,882	$ 143,723

Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues


	Year Ended December 31,
	2022		2021		2020
Alaunos Therapeutics, Inc.	$	100	$	100	$	200
Oragenics, Inc.	—		—		3,053
Intrexon Energy Partners, LLC	3,768		—		—
Intrexon Energy Partners II, LLC	10,793		—		—
Castle Creek Biosciences, Inc.	—		388		17,810

Other	—		18		145
Total (1)	$	14,661	$	506	$	21,208

Summary of Deferred Revenue

Deferred revenue consisted of the following:


	December 31,
	2022		2021
Collaboration and licensing agreements	$	1,818	$	23,023
Prepaid product and service revenues	15		1,277
Other	10		213
Total	$	1,843	$	24,513
Current portion of deferred revenue	$	25	$	1,490
Long-term portion of deferred revenue	1,818		23,023
Total	$	1,843	$	24,513

Summary of Deferred Revenue by Collaborator

Property, Plant and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consist of the following:


	December 31,
	2022		2021
Land and land improvements	$	164	$	164
Buildings and building improvements	2,592		2,592
Furniture and fixtures	457		434
Equipment	18,006		16,812
Leasehold improvements	4,333		3,366
Breeding stock	123		36
Computer hardware and software	4,562		4,823

Construction and other assets in progress	531		1,829
	30,768		30,056
Less: Accumulated depreciation and amortization	(23,439)		(21,457)
Property, plant and equipment, net	$	7,329	$	8,599

Income Taxes - Summary of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Valuation Allowance
Valuation allowance at beginning of year	$ 408,396	$ 387,348	$ 349,008
Deconsolidation of AquaBounty	0	0	0
Establishment of deferred taxes for subsidiaries included in discontinued operations	0	0	0
Current year continuing operations	16,292	26,558	21,481
Discontinued operations treated as asset sales	(27,909)	(3,626)	7,805
Discontinued operations related to MBP Titan	0	(1,186)	8,019
Foreign currency translation adjustment	(391)	(698)	1,035
Valuation allowance at end of year	401,086	408,396	387,348
Adoption of ASU 2020-06
Valuation Allowance
Adoption of ASU 2020-06	$ 4,698	$ 0	$ 0

Lines of Credit and Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Schedule of Long-Term Debt Instruments

Long-term debt consists of the following:


	December 31,
	2022		2021
Convertible debt	$	43,219	$	179,882

Other	—		52
Long-term debt	43,219		179,934
Less current portion	43,219		52
Long-term debt, less current portion	$	—	$	179,882

Components of Interest Expense

The components of interest expense related to the Convertible Notes were as follows:


	Year Ended December 31,
	2022		2021		2020
Cash interest expense	$	5,727	$	7,000	$	7,000
Non-cash interest expense	1,042		11,735		10,587
Total interest expense	$	6,769	$	18,735	$	17,587

Schedule of Maturities of Long-Term Debt

Future maturities of long-term debt as of December 31, 2022 are as follows:


2023	$	43,340
2024	—
2025	—
2026	—
2027	—
Thereafter	—
Total	$	43,340

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Inventory

12 Months Ended

Dec. 31, 2022

Inventory Disclosure [Abstract]

Inventory

InventoryInventory consists of the following:


	December 31,
	2022		2021
Supplies, embryos and other production materials	$	15	$	23

MiniSwines	272		303

Total inventory	$	287	$	326

Consolidated Statements of Cash Flows (Reconciliation of Cash) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 4,858	$ 36,423
Restricted cash	43,339	0
Cash and cash equivalents included in current assets held for sale or abandonment	0	6,497
Restricted cash included in other assets	399	423
Cash, cash equivalents, and restricted cash	$ 48,596	$ 43,343

Operating Leases - Lease Terms and Discount Rates (Details)	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted average remaining lease term (years)	6 years 1 month 2 days	6 years 8 months 19 days
Weighted average discount rate	11.05%	10.94%

Fair Value Measurements

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value MeasurementsThe carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.

Assets

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2022:


	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2022
Assets
United States government debt securities	$	—	$	50,995	$	—	$	50,995

Certificates of deposit	—		97		—		97
Total	$	—	$	51,092	$	—	$	51,092

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021:


	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2021
Assets
United States government debt securities	$	—	$	120,705	$	—	$	120,705

Certificates of deposit	—		97		—		97
Total	$	—	$	120,802	$	—	$	120,802

The method used to estimate the fair value of the Level 2 short-term and long-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets.

Liabilities

The carrying values of the Company's long-term debt, excluding the Convertible Notes, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates.

The calculated fair value of the Convertible Notes (Note 11) was approximately $43,000 and $160,000 as of December 31, 2022 and 2021, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $43,219 and $179,882 as of December 31, 2022 and 2021, respectively.

See Notes 9 and 10 for discussion of non-recurring fair value estimates used in calculating impairment charges recorded during the years ended December 31, 2022, 2021, and 2020.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Share-Based Payments - Summary of Information About Stock Options Outstanding (Details) - Precigen Stock Option Plans - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, number of options (in shares)	15,201,276	12,260,187
Options outstanding, weighted average exercise price (in usd per share)	$ 10.41	$ 14.06	$ 15.53	$ 21.94
Options outstanding, weighted average remaining life (in years)	6 years 10 months 13 days	6 years 9 months 14 days
Options outstanding, aggregate intrinsic value	$ 7,703	$ 1,329
Options exercisable, number of options (in shares)	8,559,359	7,078,840
Options exercisable, weighted average exercise price (in usd per share)	$ 13.58	$ 16.69
Options exercisable, weighted average remaining life (in years)	5 years 9 months	5 years 7 months 2 days
Options exercisable, aggregate intrinsic value	$ 2,724	$ 1,327
Price range 1
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 1.22	$ 1.55
Stock options, exercise price range, upper limit (in usd per share)	$ 2.33	$ 5.95
Options outstanding, number of options (in shares)	4,944,982	3,290,348
Options outstanding, weighted average exercise price (in usd per share)	$ 2.17	$ 4.64
Options outstanding, weighted average remaining life (in years)	8 years 10 months 6 days	8 years 2 months 4 days
Options outstanding, aggregate intrinsic value	$ 7,630	$ 1,329
Options exercisable, number of options (in shares)	1,602,732	2,031,348
Options exercisable, weighted average exercise price (in usd per share)	$ 2.02	$ 4.15
Options exercisable, weighted average remaining life (in years)	8 years 2 months 15 days	7 years 11 months 23 days
Options exercisable, aggregate intrinsic value	$ 2,708	$ 1,327
Price range 2
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 2.53	$ 6.01
Stock options, exercise price range, upper limit (in usd per share)	$ 8.17	$ 11.90
Options outstanding, number of options (in shares)	3,903,425	3,568,102
Options outstanding, weighted average exercise price (in usd per share)	$ 6.39	$ 9.69
Options outstanding, weighted average remaining life (in years)	7 years 6 months 7 days	8 years 5 months 15 days
Options outstanding, aggregate intrinsic value	$ 73	$ 0
Options exercisable, number of options (in shares)	2,170,946	833,104
Options exercisable, weighted average exercise price (in usd per share)	$ 6.14	$ 9.79
Options exercisable, weighted average remaining life (in years)	7 years 2 months 8 days	7 years 10 months 24 days
Options exercisable, aggregate intrinsic value	$ 16	$ 0
Price range 3
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 8.20	$ 12.01
Stock options, exercise price range, upper limit (in usd per share)	$ 17.85	$ 20.94
Options outstanding, number of options (in shares)	3,601,175	3,068,340
Options outstanding, weighted average exercise price (in usd per share)	$ 14.45	$ 18.59
Options outstanding, weighted average remaining life (in years)	6 years 9 months 10 days	6 years 1 month 2 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	2,033,987	1,880,991
Options exercisable, weighted average exercise price (in usd per share)	$ 14.33	$ 19.16
Options exercisable, weighted average remaining life (in years)	6 years 7 months 6 days	4 years 11 months 4 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 4
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 18.19	$ 21.13
Stock options, exercise price range, upper limit (in usd per share)	$ 45.11	$ 45.69
Options outstanding, number of options (in shares)	2,626,227	2,332,393
Options outstanding, weighted average exercise price (in usd per share)	$ 24.65	$ 28.06
Options outstanding, weighted average remaining life (in years)	2 years 6 months 18 days	3 years 2 months 19 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	2,626,227	2,332,393
Options exercisable, weighted average exercise price (in usd per share)	$ 24.65	$ 28.06
Options exercisable, weighted average remaining life (in years)	2 years 6 months 18 days	3 years 2 months 19 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 5
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 45.69	$ 47.35
Stock options, exercise price range, upper limit (in usd per share)	$ 45.69	$ 47.35
Options outstanding, number of options (in shares)	125,467	1,004
Options outstanding, weighted average exercise price (in usd per share)	$ 45.69	$ 47.35
Options outstanding, weighted average remaining life (in years)	2 years 29 days	3 years 6 months 3 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	125,467	1,004
Options exercisable, weighted average exercise price (in usd per share)	$ 45.69	$ 47.35
Options exercisable, weighted average remaining life (in years)	2 years 29 days	3 years 6 months 3 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0

Segments - Adjusted EBITDA by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ (40,042)	$ (38,856)	$ (31,374)
Biopharmaceuticals
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	(45,039)	(45,754)	(35,378)
Exemplar
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ 4,997	$ 6,898	$ 4,004

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	12 Months Ended
	Dec. 31, 2015 USD ($) board_seat	Dec. 31, 2022	Dec. 31, 2021 USD ($)
Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Maximum additional capital contributions committed	$ 10,000,000
Total number of seats on the joint venture's governing board \| board_seat	5
Total number of seats on the joint venture's governing board, internally selected \| board_seat	1
Total number of seats on the joint venture's governing board, externally selected \| board_seat	4
Intrexon Energy Partners II, LLC \| Intrexon Energy Partners II, LLC \| Precigen And Remaining IEP Investors
Schedule Of Investments In Joint Venture [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners		2.90%
Investor \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Capital contribution	$ 18,000,000
Maximum additional capital contributions committed	10,000,000
All Investors \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	4,000,000
Other accrued liabilities \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ (435,000)
Intrexon Energy Partners II, LLC \| Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000

Short-term and Long-term Investments (Tables)

12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2022:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Aggregate Fair Value
United States government debt securities	$	51,755	$	—	$	(760)	$	50,995
Certificates of deposit	97		—		—		97
Total	$	51,852	$	—	$	(760)	$	51,092

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Aggregate Fair Value
United States government debt securities	$	121,036	$	—	$	(331)	$	120,705
Certificates of deposit	97		—		—		97
Total	$	121,133	$	—	$	(331)	$	120,802

Contractual Obligation, Fiscal Year Maturity

The estimated fair value of available-for-sale investments classified by their contractual maturities as of December 31, 2022 was:


Due within one year	$	51,092
After one year through two years	—
Total	$	51,092

Segments - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Exemplar
Segment Reporting Information [Line Items]
Percentage of revenue attributable to customer	59.60%	61.50%	51.90%
Non-US
Segment Reporting Information [Line Items]
Revenues	$ 233	$ 378	$ 595
Long-lived assets	$ 2,591	$ 4,463

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (79,966)	$ (110,967)	$ (104,524)
Domestic
Income Tax [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(76,572)	(107,582)	(97,982)
Foreign
Income Tax [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (3,394)	$ (3,385)	$ (6,542)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Defined Contribution Plans - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Defined contribution plans, cost recognized	$ 564	$ 388	$ 397

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets
Allowance for doubtful accounts	$ 53	$ 1,506
Inventory	0	370
Equity securities and investments in affiliates	258	570
Property, plant and equipment	284	0
Intangible assets	69,807	80,540
Accrued liabilities	3,219	3,090
Lease liabilities	2,182	2,839
Stock-based compensation	17,106	15,227
Deferred revenue	474	7,300
Capitalized research and development cost	16,318	0
Research and development tax credits	12,160	11,168
Net operating, capital loss, and interest expense carryforwards	288,397	301,791
Total deferred tax assets	410,258	424,401
Less: (Valuation allowance)	401,086	408,396	$ 387,348	$ 349,008
Net deferred tax assets	9,172	16,005
Deferred tax liabilities
Property, plant and equipment	0	250
Right-of-use assets	2,071	2,735
Foreign intangible asset	9,364	10,861
Long-term debt	0	4,698
Total deferred tax liabilities	11,435	18,544
Net deferred tax liabilities included in continuing operations	$ (2,263)	$ (2,539)

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Computed statutory income tax benefit from continuing operations	$ (16,793)	$ (23,303)	$ (21,950)
State and provincial income tax benefit, net of federal income taxes	(2,884)	(4,670)	(5,199)
Nondeductible stock based compensation	179	832	5,709
Nondeductible officer compensation	263	1,459	728
Impairment of goodwill	101	0	0
Nondeductible equity investment loss	3,093	0	0
Research and development tax incentives	(991)	(958)	(524)
Acquisition and internal restructuring transaction costs	0	0	0
United States-foreign rate differential	18	(32)	(21)
Other, net	533	(46)	(306)
Income tax reconciliation income tax benefit before valuation allowance, total	(16,481)	(26,718)	(21,563)
Change in valuation allowance for deferred tax assets	16,292	26,558	21,481
Total income tax benefit from continuing operations	$ (189)	$ (160)	$ (82)

Inventory (Tables)

12 Months Ended

Dec. 31, 2022

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:


	December 31,
	2022		2021
Supplies, embryos and other production materials	$	15	$	23

MiniSwines	272		303

Total inventory	$	287	$	326

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill
Beginning of year	$ 37,554
Impairment	(482)	$ 0	$ (9,635)
Foreign currency translation adjustments	(149)	(215)
End of year	36,923	37,554
Continuing Operations
Goodwill
Beginning of year	37,554	37,769
Impairment	(482)	0	0
Foreign currency translation adjustments	(149)	(215)
End of year	$ 36,923	$ 37,554	$ 37,769

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Goodwill and Intangible Assets, Net - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) reporting_unit	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated goodwill impairment losses	$ 14,483	$ 14,001
Impairment of goodwill	$ 482	0	$ 9,635
Number of reporting units impaired \| reporting_unit	1
Amortization expense	$ 4,798	$ 5,273	$ 5,243

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Revenue Recognition

The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Collaboration and licensing revenues

The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.

The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.

At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.

The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.

Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.

The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.

Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.

As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.

From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.

Product and service revenues

The Company's product and service revenues are generated primarily through Exemplar which generates product and service revenues through the development and sale of genetically engineered miniature swine models. The Company evaluates each promised product or service under its contracts and identifies performance obligations for each distinct product or service. The Company then allocates the transaction price of the contract to each performance obligation, recognizing the transaction price as revenue at a point in time when control of the promised product or over time when the promised service is rendered. We typically recognize revenue using an out-based measure, generally time elapsed or days of service, to measure progress and

transfer of the control of the performance obligation to the customer. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.

Research and Development

The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.

Cash and Cash Equivalents

Cash and Cash EquivalentsAll highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer.

Restricted Cash

This cash is restricted for the permitted purposes related to our Convertible Notes, including the resolution of such notes.

Short-term and Long-Term Investments

Short-term and Long-Term InvestmentsAs of December 31, 2022 and 2021 short-term and long-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date.

Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:


Level 1:			Quoted prices in active markets for identical assets and liabilities;

Level 2:			Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and

Level 3:			Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk

Due to the Company's fixed rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2022, gross unrealized losses on the Company's short-term investments were not material. From time

to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Although the Company has no intent to liquidate such investments, depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company manages credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.

Equity Method Investments

Equity Method InvestmentsThe Company has accounted for its investment in its joint ventures ("JVs) using the equity method of accounting based upon relative ownership interest.

Variable Interest Entities

Variable Interest EntitiesThe Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.

Accounts Receivables

Accounts Receivable

The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of accounts receivables. Balances are written off at the point when collection attempts have been exhausted.

Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the

straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:


			Years
Land improvements			9–15
Buildings and building improvements			9–15
Furniture and fixtures			4–7
Equipment			2–7
Breeding stock			2
Computer hardware and software			1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to eleven years.

Operating Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.

Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.

Goodwill

Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.

When a the quantitative goodwill impairment test is performed, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.

The Company performs its annual impairment review of goodwill on December 31 and performs increment impairment reviews if a triggering event occurs prior to the annual impairment review.

When the Company performs quantitative evaluations, the fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital.

Intangible Assets

Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization.

The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three to eighteen years for the patents, developed technologies, and know-how; customer relationships; and trademarks.

Impairment of Long-Lived Assets

Long-lived assets to be held and used, including property, plant and equipment, ROU Assets, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.

Foreign Currency Translation

The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.

The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises.

Share-Based Payments

Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option.

The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022, 2021, and 2020 are set forth in the table below:


	2022	2021	2020
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	87%–89%	87%–90%	59%–90%
Expected term (years)	6.25	6.00	6.00-10.00
Risk-free interest rate	1.64%–4.12%	0.61%–1.33%	0.36%–1.80%

Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant.

Net Income (Loss) per Share

Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net income (loss) per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive as described in the next paragraph, therefore, basic and diluted net income (loss) per share were the same for all periods presented. See Note13 for the further discussion of the Company's Share Lending Agreement.

Segment Information

The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. The financial information regularly reviewed by the CODM consists of (i) Biopharmaceuticals and (ii) Exemplar, each an operating segment which were also determined to be reportable segments. The Biopharmaceuticals reportable segment is primarily comprised of the Company's legal entities of PGEN Therapeutics and ActoBio. See Note 1 for a description of PGEN Therapeutics, ActoBio and Exemplar. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's

finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, gain or loss on disposals of assets, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio. Note 18 for further discussion of the Company's segments.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Recently Adopted and Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"). Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments.

We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported long-term debt outstanding, net of current portion, of $18,196, a decrease to our additional paid-in capital of $36,868, and a corresponding cumulative-effect reduction to our opening accumulated deficit of $18,672. Upon the adoption of ASU 2020-06, non-cash interest expense related to existing convertible debt outstanding at January 1, 2022 was expected to be reduced by approximately $11,800 for the year ended December 31, 2022, and did not have an impact on our consolidated cash flows. The use of the if-converted method did not have an impact on our overall earnings per share calculation.

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended		12 Months Ended
	Sep. 30, 2020 shares	Jul. 31, 2018 USD ($) day $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Mar. 06, 2023 USD ($)	Aug. 18, 2022 USD ($)	Sep. 30, 2018 USD ($)
Debt Instrument [Line Items]
Deferred income taxes			$ (150,000)	$ (167,000)	$ (156,000)
Long-term debt, net of current portion			0	179,882,000
Additional paid-in capital			(1,998,314,000)	(2,022,701,000)
Accumulated deficit			1,868,567,000	1,915,556,000
Restricted Cash							$ 200,000,000
Gain (Loss) on Extinguishment of Debt			961,000	0	0
Interest payable			759,000
Subsequent Event
Debt Instrument [Line Items]
Debt instrument, repurchased face amount						$ 15,460,000
Debt instrument, repurchase amount						$ 15,305,000
Cumulative effect of adoption of ASU 2020-06
Debt Instrument [Line Items]
Long-term debt, net of current portion				18,196,000
Additional paid-in capital				36,868,000
Accumulated deficit				(18,672,000)
Discontinued Operations, Held-for-sale or Disposed of by Sale \| Trans Ova
Debt Instrument [Line Items]
Restricted cash, current			43,339,000
Convertible debt
Debt Instrument [Line Items]
Extinguishment of Debt, Amount			156,660,000
Gain (Loss) on Extinguishment of Debt			961,000
Convertible debt \| Precigen ActoBio, Inc. \| Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage								3.00%
Interest expense					$ 616,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount		$ 200,000,000	$ 43,340,000
Proceeds from long-term debt, net of issuance costs		193,958,000
Debt issuance costs		$ 6,042,000
Debt instrument, interest rate, stated percentage		3.50%
Conversion rate		58.6622
Principal amount used in conversion		$ 1,000
Conversion price (in usd per share) \| $ / shares		$ 17.05	$ 17.05
Debt instrument redemption price, percentage		100.00%
Carrying value of convertible debt		$ 143,723,000	$ 43,219,000	$ 179,882,000
Adjustments to additional paid in capital, equity component of convertible debt		50,235,000
Deferred income taxes		$ 13,367,000
Effective interest rate on convertible notes			4.25%
Convertible notes, unamortized discount and issuance costs			$ 121,000
3.5% Convertible Notes Due 2023 \| Minimum
Debt Instrument [Line Items]
Common stock price trading days \| day		20
Common stock price consecutive trading days \| day		30
Percentage of common share price over conversion price for conversion		130.00%
3.5% Convertible Notes Due 2023 \| Maximum
Debt Instrument [Line Items]
Common stock price trading days \| day		5
Common stock price consecutive trading days \| day		5
Debt instrument redemption price, percentage		98.00%
ActoBio Notes
Debt Instrument [Line Items]
Common stock issued upon conversion of long-term debt (in shares) \| shares	6,293,402
Harvest Intrexon Enterprise Fund I, LP \| Precigen ActoBio, Inc.
Debt Instrument [Line Items]
Aggregate principal amount								$ 30,000,000

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - Trans Ova (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$ 10,765	$ 13,761	$ 17,516
Equity in net income (loss) of affiliates	(862)	3	1,176
Provision for credit losses	944	1,268	899
Stock-based compensation expense	10,206	13,904	18,366
Cash flows from investing activities
Proceeds from repayment of notes receivable	0	3,754	2,942
Purchases of property, plant and equipment	(4,924)	(7,247)	(7,527)
Trans Ova \| Discontinued Operations, Held-for-sale or Disposed of by Sale
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	3,574	5,622	6,750
Impairment of goodwill	0	0	106
(Gain) loss on disposal of assets, net	421	561	4,325
Equity in net income (loss) of affiliates	0	0	535
Provision for credit losses	944	1,128	899
Stock-based compensation expense	9	350	738
Cash flows from investing activities
Proceeds from repayment of notes receivable	0	3,689	0
Purchases of property, plant and equipment	(3,529)	(4,694)	(6,365)
Proceeds from sales of assets	$ 594	$ 1,894	$ 2,387

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Risks and Uncertainties

The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of therapeutic product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its therapeutic product candidates.

The Company is closely monitoring the impact of COVID-19 on all aspects of its businesses. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses.

See Note 3 for further discussion of the impact of COVID-19 on MBP Titan.

Revenue Recognition

Collaboration and licensing revenues

Product and service revenues

transfer of the control of the performance obligation to the customer. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.

Research and Development

The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December 31, 2022 and 2021, the Company had research and development commitments with third parties that had not yet been incurred totaling $19,909 and $22,301, respectively. The commitments are generally cancellable by the Company by providing written notice at least sixty days before the desire termination date.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer. As of December 31, 2022 and 2021, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $2,985 and $20,697, respectively, which is included in cash and cash equivalents in the accompanying consolidated balance sheets.

Restricted Cash

Included in the Consolidated Balance Sheet as of December 31, 2022, is restricted cash of $43,339. This cash is restricted for the permitted purposes related to our Convertible Notes, including the resolution of such notes.

Short-term and Long-Term Investments

As of December 31, 2022 and 2021 short-term and long-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date.

Fair Value of Financial Instruments


Level 1:			Quoted prices in active markets for identical assets and liabilities;

Level 2:			Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and

Level 3:			Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk

Equity Method Investments

The Company has accounted for its investment in its joint ventures ("JVs) using the equity method of accounting based upon relative ownership interest. At December 31, 2022, the Company no longer held any investments in JVs. See additional discussion related to certain of the Company's historical JVs in Note 4.

Variable Interest Entities

The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.

As of December 31, 2021, the Company determined that certain of its collaborators and JVs were VIEs. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. In July 2022, the Company obtained substantially all of the membership interests that were previously owned by others of these VIEs, and began consolidating those entities at the time of the acquisitions. The operations and financial position of those entities were not material as of or for the period ended July 2022. See Note 4 and Note 16 for additional discussion. During the quarter ended December 31, 2022, these VIEs were liquidated.

Accounts Receivable

Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.

The following table shows the activity in the allowance for credit losses for the years ended December 31, 2022, 2021, and 2020:


	2022		2021		2020
Beginning balance	$	1,693	$	1,509	$	2,312
Charged to operating expenses	—		140		—
Write offs of accounts receivable, net of recoveries	(1,509)		44		(803)
Ending balance	184		1,693		1,509

Property, Plant and Equipment

straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:


			Years
Land improvements			9–15
Buildings and building improvements			9–15
Furniture and fixtures			4–7
Equipment			2–7
Breeding stock			2
Computer hardware and software			1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to eleven years.

Operating Leases

Goodwill

The Company performs its annual impairment review of goodwill on December 31 and performs increment impairment reviews if a triggering event occurs prior to the annual impairment review.

See Notes 3 and 10 for additional discussion regarding goodwill impairment charges recorded in the year ended December 31, 2022 and 2020.

Intangible Assets

Impairment of Long-Lived Assets

See Notes 3 and 9 for additional discussion of impairment of long-lived assets for the years ended December 31, 2022, 2021 and 2020.

Foreign Currency Translation

Income Taxes

The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises. There was no impact from GILTI to the accompanying consolidated financial statements.

Share-Based Payments


	2022	2021	2020
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	87%–89%	87%–90%	59%–90%
Expected term (years)	6.25	6.00	6.00-10.00
Risk-free interest rate	1.64%–4.12%	0.61%–1.33%	0.36%–1.80%

Net Income (Loss) per Share

In accordance with ASC 260, the control number for determining whether including potential common shares in the diluted earning per share, or EPS, computation would be antidilutive should be income from continuing operations. As a result, if there is a loss from continuing operations, diluted EPS would be computed in the same manner as basic EPS is computed, even if the entity has net income after adjusting for a discontinued operation. The following potentially dilutive securities as of December 31, 2022, 2021, and 2020, have been excluded from the computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:


	December 31,
	2022	2021	2020

Options	15,201,276	12,260,187	11,255,896
Restricted stock units	697,815	468,481	1,727,712
Warrants	—	121,888	133,264
Total	15,899,091	12,850,556	13,116,872

In addition, the Company's Convertible Notes convert at an exercise price of approximately $17.05 per share of common stock, representing approximately 2,542,420 shares at December 31, 2022 and 11,732,440 shares at both December 31, 2021 and 2020. The shares underlying the Convertibles Notes were considered for the dilutive calculation but were excluded in all years presented as their effect is antidilutive. See Note 11 for further discussion of the Convertible Notes.

Segment Information

Use of Estimates

Recently Adopted Accounting Pronouncements

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 28,317	$ (92,166)	$ (170,521)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(431)	(344)	6
Gain (loss) on foreign currency translation adjustments	(3,262)	(3,450)	4,502
Release of cumulative foreign currency translation adjustments to net loss from discontinued operations	0	0	26,957
Comprehensive Income (loss)	$ 24,624	$ (95,960)	$ (139,056)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

Goodwill and Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021, are as follows:


	2022		2021
Beginning of year	$	37,554	$	37,769

Impairment	(482)		—
Foreign currency translation adjustments	(149)		(215)
End of year	$	36,923	$	37,554

Schedule of Intangible Assets

Intangible assets consist of the following as of December 31, 2022:


	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net
Patents, developed technologies and know-how	16.4	$	80,892	$	(36,437)	$	44,455
Customer relationships	3.0	1,600		(1,600)		—
Trademarks	5.0	200		(200)		—

Total		$	82,692	$	(38,237)	$	44,455

Intangible assets consist of the following as of December 31, 2021:


	Gross Carrying Amount		Accumulated Amortization		Net
Patents, developed technologies and know-how	$	85,173	$	(32,882)	$	52,291
Customer relationships	1,600		(1,600)		—
Trademarks	200		(200)		—

Total	$	86,973	$	(34,682)	$	52,291

Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense

Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:


2023	$	4,773
2024	4,773
2025	4,773
2026	4,773
2027	4,773
Thereafter	20,590
Total	$	44,455

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 4,858	$ 36,423
Restricted cash	43,339	0
Short-term investments	51,092	72,240
Receivables
Trade, less allowance for credit losses of $184 as of both December 31, 2022 and 2021	959	1,341
Related parties, less allowance for credit losses of $0 and $1,509 as of December 31, 2022 and 2021	19	73
Other	12,826	566
Inventory	287	326
Prepaid expenses and other	4,779	5,471
Current assets held for sale	0	40,188
Total current assets	118,159	156,628
Long-term investments	0	48,562
Property, plant and equipment, net	7,329	8,599
Intangible assets, net	44,455	52,291
Goodwill	36,923	37,554
Right-of-use assets	8,086	9,990
Other assets	1,025	936
Noncurrent assets held for sale	0	45,296
Total assets	215,977	359,856
Current liabilities
Accounts payable	4,068	3,112
Accrued compensation and benefits	6,377	7,856
Other accrued liabilities	23,747	7,817
Deferred revenue	25	1,490
Current portion of long-term debt	43,219	52
Current portion of lease liabilities	1,209	1,393
Related party payables	0	74
Current liabilities held for sale	0	12,851
Total current liabilities	78,645	34,645
Long-term debt, net of current portion	0	179,882
Long-term portion of deferred revenue	1,818	23,023
Lease liabilities, net of current portion	6,992	8,747
Deferred tax liabilities	2,263	2,539
Long-term liabilities held for sale	0	3,672
Total liabilities	89,718	252,508
Commitments and Contingencies
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of December 31, 2022 and 2021; and 208,150,021 shares and 206,739,874 shares issued and outstanding as of December 31, 2022 and 2021, respectively	0	0
Additional paid-in capital	1,998,314	2,022,701
Accumulated deficit	(1,868,567)	(1,915,556)
Accumulated other comprehensive (loss) income	(3,488)	203
Total shareholders' equity	126,259	107,348
Total liabilities and shareholders' equity	$ 215,977	$ 359,856

Operating Leases - Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$ 2,493	$ 3,199	$ 3,679
Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases)	$ 466	$ 4,868	$ 112

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

The components of loss from continuing operations before income taxes are presented below:


	Year Ended December 31,
	2022		2021		2020
Domestic	$	(76,572)	$	(107,582)	$	(97,982)
Foreign	(3,394)		(3,385)		(6,542)
Loss from continuing operations before income taxes	$	(79,966)	$	(110,967)	$	(104,524)

The components of income tax benefit from continuing operations are presented below:


	Year Ended December 31,
	2022		2021		2020
United States federal income taxes:

Deferred	$	37	$	37	$	37
Foreign income taxes:
Current	(39)		7		74
Deferred	(198)		(215)		(204)
State income taxes:

Deferred	11		11		11
Income tax benefit from continuing operations	$	(189)	$	(160)	$	(82)

Income tax benefit from continuing operations for the years ended December 31, 2022, 2021, and 2020 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following:


	2022		2021		2020
Computed statutory income tax benefit from continuing operations	$	(16,793)	$	(23,303)	$	(21,950)
State and provincial income tax benefit, net of federal income taxes	(2,884)		(4,670)		(5,199)
Nondeductible stock based compensation	179		832		5,709
Nondeductible officer compensation	263		1,459		728
Impairment of goodwill	101		—		—
Nondeductible equity investment loss	3,093		—		—
Research and development tax incentives	(991)		(958)		(524)
Acquisition and internal restructuring transaction costs	—		—		—



United States-foreign rate differential	18		(32)		(21)
Other, net	533		(46)		(306)
	(16,481)		(26,718)		(21,563)
Change in valuation allowance for deferred tax assets	16,292		26,558		21,481
Total income tax benefit from continuing operations	$	(189)	$	(160)	$	(82)

The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December 31, 2022 and 2021, are as follows:


	2022		2021
Deferred tax assets
Allowance for doubtful accounts	$	53	$	1,506
Inventory	—		370
Equity securities and investments in affiliates	258		570
Property, plant and equipment	284		—
Intangible assets	69,807		80,540
Accrued liabilities	3,219		3,090
Lease liabilities	2,182		2,839
Stock-based compensation	17,106		15,227
Deferred revenue	474		7,300
Capitalized research and development cost	16,318		—
Research and development tax credits	12,160		11,168

Net operating, capital loss, and interest expense carryforwards	288,397		301,791
Total deferred tax assets	410,258		424,401
Less: (Valuation allowance)	401,086		408,396
Net deferred tax assets	9,172		16,005
Deferred tax liabilities
Property, plant and equipment	—		250
Right-of-use assets	2,071		2,735

Foreign intangible asset	9,364		10,861
Long-term debt	—		4,698
Total deferred tax liabilities	11,435		18,544
Net deferred tax liabilities included in continuing operations	$	(2,263)	$	(2,539)

Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December 31, 2022, 2021, and 2020 was as follows:


	2022		2021		2020
Valuation allowance at beginning of year	$	408,396	$	387,348	$	349,008
Increase (decrease) in valuation allowance as a result of

Deconsolidation of AquaBounty	—		—		—
Establishment of deferred taxes for subsidiaries included in discontinued operations	—		—		—
Current year continuing operations	16,292		26,558		21,481
Discontinued operations treated as asset sales	(27,909)		(3,626)		7,805
Discontinued operations related to MBP Titan	—		(1,186)		8,019





Adoption of ASU 2020-06	4,698		—		—
Foreign currency translation adjustment	(391)		(698)		1,035
Valuation allowance at end of year	$	401,086	$	408,396	$	387,348

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and

liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.

The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December 31, 2022, all such limited losses applicable to Precigen, other than losses inherited via acquisition, have been fully utilized. As of December 31, 2022, approximately $41,400 of the Company's domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction.

As of December 31, 2022, the Company has net operating loss carryforwards for United States federal income tax purposes of approximately $819,100 available to offset future taxable income, including approximately $604,200 generated after 2017, United States capital loss carryforwards of approximately $212,500, and federal and state research and development tax credits of approximately $12,100, prior to consideration of annual limitations that may be imposed under Section 382. Net operating loss carryforwards generated prior to 2018 began to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. As of December 31, 2022, the Company's foreign subsidiaries have foreign loss carryforwards of approximately $71,000, most of which do not expire.

As of December 31, 2022, the Company's direct foreign subsidiaries included in continuing operations had accumulated deficits of approximately $26,184. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes.

The Company and its subsidiaries do not have material unrecognized tax benefits as of December 31, 2022. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating and capital losses and research and development tax credits.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Share-Based Payments (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation costs included in the consolidated statements of operations are presented below:


	Year Ended December 31,
	2022		2021		2020
Cost of products and services	$	110	$	161	$	66

Research and development	2,188		2,706		611
Selling, general and administrative	7,899		10,687		18,331
Discontinued operations	9		350		(642)
Total	$	10,206	$	13,904	$	18,366

Schedule of Stock Option Activity

Stock option activity was as follows:


	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2019	9,022,282	$	21.94	6.10
Granted	5,693,498	10.03
Exercised	(30,061)	(3.88)
Forfeited	(976,324)	(15.47)
Expired	(2,453,499)	26.53
Balances at December 31, 2020	11,255,896	15.53		7.25
Granted	2,058,820	7.59
Exercised	(127,883)	(4.75)
Forfeited	(305,293)	(7.02)
Expired	(621,353)	(24.61)
Balances at December 31, 2021	12,260,187	14.06		6.79
Granted	4,451,890	2.22
Exercised	(375)	(2.28)
Forfeited	(567,179)	(5.19)
Expired	(943,247)	(22.32)
Balances at December 31, 2022	15,201,276	10.41		6.87
Exercisable at December 31, 2022	8,559,359	13.58		5.75

Summary of Information About Stock Options Outstanding

The following table summarizes additional information about stock options outstanding as of December 31, 2022:


					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	1.22	—	$	2.33	4,944,982	$	2.17	8.85	$	7,630	1,602,732	$	2.02	8.21	$	2,708
$	2.53	—	$	8.17	3,903,425	6.39		7.52	73		2,170,946	6.14		7.19	16
$	8.20	—	$	17.85	3,601,175	14.45		6.78	—		2,033,987	14.33		6.60	—
$	18.19	—	$	45.11	2,626,227	24.65		2.55	—		2,626,227	24.65		2.55	—
$	45.69				125,467	45.69		2.08	—		125,467	45.69		2.08	—
					15,201,276	$	10.41	6.87	$	7,703	8,559,359	$	13.58	5.75	$	2,724

The following table summarizes additional information about stock options outstanding as of December 31, 2021:


					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	1.55	—	$	5.95	3,290,348	$	4.64	8.18	$	1,329	2,031,348	$	4.15	7.98	$	1,327
$	6.01	—	$	11.90	3,568,102	9.69		8.46	—		833,104	9.79		7.90	—
$	12.01	—	$	20.94	3,068,340	18.59		6.09	—		1,880,991	19.16		4.93	—
$	21.13	—	$	45.69	2,332,393	28.06		3.22	—		2,332,393	28.06		3.22	—
$	47.35	—	$	47.35	1,004	47.35		3.51	—		1,004	47.35		3.51	—
					12,260,187	$	14.06	6.79	$	1,329	7,078,840	$	16.69	5.59	$	1,327

Schedule of Restricted Stock Unit Activity

RSU activity was as follows:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2019	1,781,982	$	8.71	1.24
Granted	3,157,390	3.09
Vested	(2,802,593)	(3.99)
Forfeited	(409,067)	(8.59)
Balances at December 31, 2020	1,727,712	6.11		0.42
Granted	462,019	7.87
Vested	(1,624,013)	(5.76)
Forfeited	(97,237)	(8.96)
Balances at December 31, 2021	468,481	8.47		0.33
Granted	1,387,831	2.12
Vested	(1,125,785)	4.29
Forfeited	(32,712)	7.26
Balances at December 31, 2022	697,815	2.66		0.13

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 28,317	$ (92,166)	$ (170,521)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	10,765	13,761	17,516
Loss on disposals of assets, net	421	150	4,442
Impairment of goodwill	482	0	9,635
Impairment of other noncurrent assets	638	543	13,326
Gain on sale of discontinued operations	(94,702)	0	(672)
Loss on release of cumulative foreign currency translation adjustment	0	0	26,957
Loss on settlement agreement	0	0	11,436
Gain on debt retirement	(961)	0	0
Unrealized and realized depreciation on equity securities and preferred stock, net	0	0	106
Amortization of premiums (discounts) on investments, net	832	1,232	(699)
Equity in net (income) loss of affiliates	(862)	3	1,176
Stock-based compensation expense	10,206	13,904	18,366
Shares issued as payment for services	576	577	1,006
Provision for credit losses	944	1,268	899
Accretion of debt discount and amortization of deferred financing costs	1,042	11,735	10,587
Deferred income taxes	(150)	(167)	(156)
Noncash (gain) loss on termination of leases	0	(5,831)	191
Other noncash items	106	24	35
Receivables:
Trade	(2,229)	(6,176)	2,214
Related parties	54	(54)	258
Other	(11,338)	(330)	1,853
Inventory	2,341	(1,903)	2,511
Prepaid expenses and other	289	520	(812)
Other assets	(101)	305	(142)
Accounts payable	379	420	(1,097)
Accrued compensation and benefits	(37)	2,853	(789)
Other accrued liabilities	11,561	1,850	(2,682)
Deferred revenue	(23,396)	1,656	(21,045)
Lease liabilities	(107)	97	(887)
Related party payables	(78)	8	(33)
Other long-term liabilities	(37)	(50)	0
Net cash used in operating activities	(65,045)	(55,771)	(77,021)
Cash flows from investing activities
Purchases of investments	0	(174,221)	(171,360)
Sales and maturities of investments	68,441	100,168	133,000
Purchases of property, plant and equipment	(4,924)	(7,247)	(7,527)
Proceeds from sale of assets	594	3,006	6,484
Proceeds from sale of discontinued operations	162,306	0	64,240
Proceeds from repayment of notes receivable	0	3,754	2,942
Net cash provided by (used in) investing activities	226,417	(74,540)	27,779
Cash flows from financing activities
Proceeds from issuance of shares and warrants, net of issuance costs	0	121,045	35,000
Advances from lines of credit	0	0	10,005
Repayments of advances from lines of credit	0	0	(11,927)
Payments of long-term debt	(154,705)	(466)	(490)
Payments of cost to retire long-term debt	(588)	0	0
Proceeds from stock option and warrant exercises	1	608	117
Payment of stock issuance costs	0	0	0
Net cash (used in) provided by financing activities	(155,292)	121,187	32,705
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(827)	217	353
Net increase (decrease) in cash, cash equivalents, and restricted cash	5,253	(8,907)	(16,184)
Cash, cash equivalents, and restricted cash
Beginning of year	43,343	52,250	68,434
End of year	48,596	43,343	52,250
Supplemental disclosure of cash flow information
Cash paid during the period for interest	8,535	7,155	7,202
Cash paid during the period for income taxes	0	36	48
Significant noncash activities
Fair value of stock issued upon conversion of long-term debt	0	0	56,827
Fair value of stock issued in conjunction with settlement agreement	0	0	18,103
Accrued compensation paid in equity awards	1,698	0	5,100
Purchases of property and equipment included in accounts payable and other accrued liabilities	40	820	277
Proceeds from sale of assets included in receivables	$ 0	$ 14	$ 4,227

Discontinued Operations - Narrative (Details) - USD ($)		3 Months Ended	12 Months Ended
Discontinued Operations - Narrative (Details) - USD ($)	Aug. 18, 2022	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2020	Jan. 02, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses	$ 162,306,000		$ 162,306,000	$ 0	$ 64,240,000
Trans Ova \| Discontinued Operations, Held-for-sale or Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, including discontinued operation, ownership interest disposed of	100.00%
Consideration	$ 170,000,000
Contingent cash earnout payments, maximum	10,000,000
Proceeds from divestiture of businesses		$ 936,000
Restricted cash, current		43,339,000	43,339,000
Gain (loss) on disposition of assets			(421,000)	(561,000)	(4,325,000)
Trans Ova \| Discontinued Operations, Held-for-sale or Disposed of by Sale \| Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Earnout payments, maximum	$ 5,000,000
Reimbursement limit		$ 5,750,000	$ 5,750,000
MBP Titan \| Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of assets				464,000	(67,000)
Gain on lease termination				$ 4,602,000
TS Biotechnology Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration						$ 53,000,000
Discontinued operation, amount of adjustment to prior period loss on disposal, net of tax					$ 26,572,000
EnviroFlight Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration							$ 12,200,000

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Dec. 31, 2022	Feb. 15, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	PRECIGEN, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, No Par Value
Trading Symbol	PGEN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 162.1
Entity Common Stock, Shares Outstanding (in shares)		252,194,713
Documents Incorporated by Reference	Portions of the registrant's Definitive Proxy Statement for its 2023 Annual Meeting of Shareholders are incorporated by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2022.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001356090

Discontinued Operations - Summary Of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - MBP Titan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 10,765	$ 13,761	$ 17,516
Impairment of goodwill	482	0	9,635
Stock-based compensation expense	10,206	13,904	18,366
Noncash gain on termination of leases	0	(5,831)	191
Purchases of property, plant and equipment	(4,924)	(7,247)	(7,527)
Proceeds from sale of assets	$ 594	3,006	6,484
MBP Titan \| Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization		0	2,474
Impairment of goodwill		0	9,635
Impairment of other noncurrent assets		0	12,406
Loss on disposals of assets, net		(464)	67
Stock-based compensation expense		0	(34)
Noncash gain on termination of leases		(4,602)	0
Purchases of property, plant and equipment		0	(88)
Proceeds from sale of assets		$ 1,083	$ 3,952

Commitments and Contingencies - Contingencies - Additional Information (Details) - Precigen Securities Litigation - USD ($) $ in Thousands	Nov. 17, 2022	Dec. 31, 2022
Loss Contingencies [Line Items]
Loss contingency, damages awarded, value	$ 13,000
Loss contingency accrual		$ 13,000
Insurance settlements receivable		$ 12,411
Loss contingency, estimate of possible loss	$ 589

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Revenues	$ 26,909	$ 14,267	$ 31,992
Operating Expenses
Impairment of goodwill	482	0	9,635
Impairment of other noncurrent assets	638	543	13,326
Other Expense, Net
Equity in net income (loss) of affiliates	862	(3)	(1,176)
Loss from continuing operations before income taxes	(79,966)	(110,967)	(104,524)
Income tax benefit	189	160	82
Income (loss) from discontinued operations, net of income tax benefit	108,094	18,641	(66,079)
Net loss attributable to Precigen	$ 28,317	$ (92,166)	$ (170,521)
Net Income (loss) per Share
Net loss from continuing operations per share, basic (in usd per share)	$ (0.40)	$ (0.56)	$ (0.63)
Net loss from continuing operations per share, diluted (in usd per share)	(0.40)	(0.56)	(0.63)
Net income (loss) from discontinued operations per share, basic (in usd per share)	0.54	0.09	(0.39)
Net income (loss) from discontinued operations per share, diluted (in usd per share)	0.54	0.09	(0.39)
Net income (loss) per share, diluted (in usd per share)	0.14	(0.47)	(1.02)
Net Income (loss) per share, basic (in usd per share)	$ 0.14	$ (0.47)	$ (1.02)
Weighted average shares outstanding, basic (in shares)	200,360,821	197,759,900	167,065,539
Weighted average shares outstanding, diluted (in shares)	200,360,821	197,759,900	167,065,539
Collaboration and licensing agreements
Revenues
Revenues	$ 14,661	$ 506	$ 21,208
Continuing Operations
Revenues
Revenues	26,909	14,267	31,992
Operating Expenses
Research and development	47,170	47,933	39,428
Selling, general and administrative	48,006	51,994	72,694
Impairment of goodwill	482	0	0
Impairment of other noncurrent assets	638	543	814
Total operating expenses	102,635	106,215	118,310
Operating loss	(75,726)	(91,948)	(86,318)
Other Expense, Net
Interest expense	(6,774)	(18,755)	(18,209)
Interest and dividend income	133	171	1,006
Other income (expense), net	1,539	(432)	(400)
Total other expense, net	(5,102)	(19,016)	(17,603)
Equity in net income (loss) of affiliates	862	(3)	(603)
Loss from continuing operations before income taxes	(79,966)	(110,967)	(104,524)
Income tax benefit	189	160	82
Loss from continuing operations	(79,777)	(110,807)	(104,442)
Continuing Operations \| Collaboration and licensing agreements
Revenues
Revenues	14,661	506	21,208
Continuing Operations \| Product revenues
Revenues
Revenues	1,903	2,164	2,435
Continuing Operations \| Service revenues
Revenues
Revenues	10,094	11,095	7,627
Operating Expenses
Cost of product and services	6,339	5,745	5,374
Continuing Operations \| Other revenues
Revenues
Revenues	$ 251	$ 502	$ 722

Organization and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Aug. 18, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accumulated deficit	$ (1,868,567)		$ (1,915,556)
Net loss from continuing operations attributable to Precigen	$ (79,777)
Discontinued Operations, Held-for-sale or Disposed of by Sale \| Trans Ova
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, including discontinued operation, ownership interest disposed of		100.00%

- Definition

Amount after tax of income (loss) from continuing operations attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

+ Details

Share-Based Payments

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Share-Based Payments

The Company measures the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:


	Year Ended December 31,
	2022		2021		2020
Cost of products and services	$	110	$	161	$	66

Research and development	2,188		2,706		611
Selling, general and administrative	7,899		10,687		18,331
Discontinued operations	9		350		(642)
Total	$	10,206	$	13,904	$	18,366

Precigen Stock Option Plans

In April 2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December 31, 2022, there were 14,843 stock options outstanding under the 2008 Plan.

Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December 31, 2022, there were 37,000,000

shares authorized for issuance under the 2013 Plan, of which 13,288,225 stock options and 82,055 RSUs were outstanding and 12,949,460 shares were available for grant.

In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of December 31, 2022, there were 12,000,000 shares authorized for issuance under the 2019 Plan, of which 1,898,208 stock options and 615,760 RSUs were outstanding and 7,243,025 shares were available for grant.

Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have ten-year terms and vest four years from the date of grant.

Stock option activity was as follows:


	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2019	9,022,282	$	21.94	6.10
Granted	5,693,498	10.03
Exercised	(30,061)	(3.88)
Forfeited	(976,324)	(15.47)
Expired	(2,453,499)	26.53
Balances at December 31, 2020	11,255,896	15.53		7.25
Granted	2,058,820	7.59
Exercised	(127,883)	(4.75)
Forfeited	(305,293)	(7.02)
Expired	(621,353)	(24.61)
Balances at December 31, 2021	12,260,187	14.06		6.79
Granted	4,451,890	2.22
Exercised	(375)	(2.28)
Forfeited	(567,179)	(5.19)
Expired	(943,247)	(22.32)
Balances at December 31, 2022	15,201,276	10.41		6.87
Exercisable at December 31, 2022	8,559,359	13.58		5.75

Total unrecognized compensation costs related to unvested awards as of December 31, 2022 were $12,709 and are expected to be recognized over a weighted-average period of approximately 2.29 years.

The weighted average grant date fair value of options granted during 2022, 2021, and 2020 was $1.65, $5.57, and $2.98, respectively. The aggregate intrinsic value of options exercised during 2022, 2021, and 2020 was $0, $225, and $51, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise.

The following table summarizes additional information about stock options outstanding as of December 31, 2022:


					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	1.22	—	$	2.33	4,944,982	$	2.17	8.85	$	7,630	1,602,732	$	2.02	8.21	$	2,708
$	2.53	—	$	8.17	3,903,425	6.39		7.52	73		2,170,946	6.14		7.19	16
$	8.20	—	$	17.85	3,601,175	14.45		6.78	—		2,033,987	14.33		6.60	—
$	18.19	—	$	45.11	2,626,227	24.65		2.55	—		2,626,227	24.65		2.55	—
$	45.69				125,467	45.69		2.08	—		125,467	45.69		2.08	—
					15,201,276	$	10.41	6.87	$	7,703	8,559,359	$	13.58	5.75	$	2,724

The following table summarizes additional information about stock options outstanding as of December 31, 2021:


					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	1.55	—	$	5.95	3,290,348	$	4.64	8.18	$	1,329	2,031,348	$	4.15	7.98	$	1,327
$	6.01	—	$	11.90	3,568,102	9.69		8.46	—		833,104	9.79		7.90	—
$	12.01	—	$	20.94	3,068,340	18.59		6.09	—		1,880,991	19.16		4.93	—
$	21.13	—	$	45.69	2,332,393	28.06		3.22	—		2,332,393	28.06		3.22	—
$	47.35	—	$	47.35	1,004	47.35		3.51	—		1,004	47.35		3.51	—
					12,260,187	$	14.06	6.79	$	1,329	7,078,840	$	16.69	5.59	$	1,327

RSU activity was as follows:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2019	1,781,982	$	8.71	1.24
Granted	3,157,390	3.09
Vested	(2,802,593)	(3.99)
Forfeited	(409,067)	(8.59)
Balances at December 31, 2020	1,727,712	6.11		0.42
Granted	462,019	7.87
Vested	(1,624,013)	(5.76)
Forfeited	(97,237)	(8.96)
Balances at December 31, 2021	468,481	8.47		0.33
Granted	1,387,831	2.12
Vested	(1,125,785)	4.29
Forfeited	(32,712)	7.26
Balances at December 31, 2022	697,815	2.66		0.13

Total unrecognized compensation costs related to unvested RSU awards as of December 31, 2022 were $193 and are expected to be recognized over a weighted-average period of approximately 0.13 years.

Precigen currently uses authorized and unissued shares to satisfy share award exercises.

The Company's Executive Chairman ("Executive Chairman"), who previously served as an employee and executive officer until September 24, 2020, received a base salary of $200 per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale.

In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman consisting of (i) an annual retainer of $100 payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully vested stock options having a grant date fair value of $250; and (iii) an annual grant of RSUs having a grant date fair value of $250 vesting over one year. The new compensation arrangement began in calendar year 2021 and was prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. Expense associated with the arrangements above is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $813, $680, and $767 for the years ended December 31, 2022, 2021, and 2020, respectively.

Discontinued Operations - Summary of Financial Results for MBP Titan (Details) - MBP Titan - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Operating (gains) expenses	$ (4,599)	$ 40,692
Operating income (loss)	4,599	(40,692)
Income (loss) before income taxes	4,599	(40,692)
Income (loss) from discontinued operations	$ 4,599	$ (40,692)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Inventory	$ 287	$ 326
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	15	23
MiniSwines
Inventory [Line Items]
Inventory	$ 272	$ 303

Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 2,074
2024	1,882
2025	1,851
2026	1,508
2027	1,246
Thereafter	3,108
Total	11,669
Present value adjustment	(3,468)
Total	8,201
Current portion of lease liabilities	1,209	$ 1,393
Long-term portion of operating lease liabilities	$ 6,992	$ 8,747

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	12 Months Ended
	Dec. 31, 2014 USD ($)	Dec. 31, 2022 board_seat	Sep. 30, 2022 board_seat	Dec. 31, 2021 USD ($)
Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Maximum additional capital contributions committed	$ 25,000,000
Total number of seats on the joint venture's governing board \| board_seat		5
Total number of seats on the joint venture's governing board, internally selected \| board_seat			2
Total number of seats on the joint venture's governing board, externally selected \| board_seat			3
Intrexon Energy Partners, LLC \| Intrexon Energy Partners, LLC \| Precigen And Remaining IEP Investors
Schedule Of Investments In Joint Venture [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners			87.50%
Investor \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Capital contribution	$ 25,000,000
Maximum additional capital contributions committed	25,000,000
Other accrued liabilities \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment				$ (428,000)
Intrexon Energy Partners, LLC \| Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 25,000,000

Share-Based Payments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, terms of award			ten
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lock-up period		3 years
Compensation arrangement with individual, annual cash retainer	$ 100
Precigen Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			15,201,276	12,260,187	11,255,896	9,022,282
Restricted stock units outstanding (in shares)			697,815	468,481	1,727,712	1,781,982
Unrecognized compensation costs related to unvested stock option awards			$ 12,709
Recognized over weighted-average period			2 years 3 months 14 days
Weighted average grant date fair value of options granted (in usd per share)			$ 1.65	$ 5.57	$ 2.98
Aggregate intrinsic value of options exercised			$ 0	$ 225	$ 51
Precigen Stock Option Plan 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			0
Options outstanding (in shares)			14,843
Precigen Stock Option Plan 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			12,949,460
Options outstanding (in shares)			13,288,225
Number of authorized awards (in shares)			37,000,000
Restricted stock units outstanding (in shares)			82,055
Precigen Stock Option Plan 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)			7,243,025
Options outstanding (in shares)			1,898,208
Number of authorized awards (in shares)			12,000,000
Restricted stock units outstanding (in shares)			615,760
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly base salary		$ 200
Selling, general and administrative \| Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, expense			$ 813	$ 680	$ 767
Options \| Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual stock option grant, grant date fair value	250
Options \| Precigen Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, terms of award			ten-year
Vesting period of equity grant			4 years
Restricted stock units \| Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual RSU grant, grant date fair value	$ 250
Restricted stock units \| Precigen Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized over weighted-average period			1 month 17 days
Unrecognized compensation costs related to restricted stock unit awards			$ 193

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 43,340
2024	0
2025	0
2026	0
2027	0
Thereafter	0
Total	$ 43,340

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Jul. 31, 2022	Jul. 31, 2020	Feb. 29, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				$ 26,909	$ 14,267	$ 31,992
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 14,561			14,661	506	21,208
Upfront and Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized from previously deferred balances				14,561	397	20,205
Alaunos Therapeutics, Inc. \| Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				100	100	200
Oragenics, Inc. \| Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				0	0	3,053
Revenue recognized from previously deferred balances		$ 2,823
Intrexon Energy Partners, LLC \| Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				3,768	0	0
Intrexon Energy Partners II, LLC \| Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				10,793	0	0
Castle Creek Biosciences, Inc. \| Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				0	388	17,810
Revenue recognized from previously deferred balances			$ 10,000
Other revenues \| Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				$ 0	$ 18	$ 145

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 10,765	$ 13,761	$ 17,516
Impairment of goodwill	482	0	9,635
Impairment of other noncurrent assets	638	543	13,326
Gain on sale of discontinued operations	(94,702)	0	(672)
Loss on release of cumulative foreign currency translation adjustment	0	0	26,957
Unrealized and realized depreciation on equity securities and preferred stock, net	0	0	106
Equity in net (income) loss of affiliates	(862)	3	1,176
Stock-based compensation expense	10,206	13,904	18,366
Deferred income taxes	(150)	(167)	(156)
Purchases of property, plant and equipment	$ (4,924)	$ (7,247)	(7,527)
TS Biotechnology Holdings, LLC and EnviroFlight, LLC \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization			0
Impairment of goodwill			0
Impairment of other noncurrent assets			0
Gain on sale of discontinued operations			(672)
Loss on release of cumulative foreign currency translation adjustment			26,957
Unrealized and realized depreciation on equity securities and preferred stock, net			106
Stock-based compensation expense			(1,346)
Deferred income taxes			0
Purchases of property, plant and equipment			(382)
EnviroFlight Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustment			0
Equity in net (income) loss of affiliates			38
Investments in affiliates			$ 0

Segments (Tables)

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Information by Reportable Segment

Segment Adjusted EBITDA by reportable segment was as follows:


	Year Ended December 31,
	2022		2021		2020
Biopharmaceuticals	$	(45,039)	$	(45,754)	$	(35,378)
Exemplar	4,997		6,898		4,004


Segment Adjusted EBITDA for operating segments	$	(40,042)	$	(38,856)	$	(31,374)

Revenues by reportable segment were as follows:


	Year Ended December 31, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	14,894	$	12,015	$	26,909
Intersegment revenues	1,446		—		1,446
Total segment revenues	$	16,340	$	12,015	$	28,355


	Year Ended December 31, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	922	$	13,345	$	14,267
Intersegment revenues	1,637		—		1,637
Total segment revenues	$	2,559	$	13,345	$	15,904


	Year Ended December 31, 2020
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	21,780	$	10,158	$	31,938
Intersegment revenues	4,797		—		4,797
Total segment revenues	$	26,577	$	10,158	$	36,735

Goodwill by reportable segment was as follows:


	Biopharmaceuticals		Exemplar		Total
Goodwill
Balances at December 31, 2020	$	17,693	$	20,076	$	37,769


Foreign currency translation adjustments	(215)		—		(215)
Balances at December 31, 2021	17,478		20,076		37,554


Foreign currency translation adjustments	(149)		—		(149)
Impairments	(482)		—		(482)
Balances at December 31, 2022	$	16,847	$	20,076	$	36,923

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Year Ended December 31,
	2022		2021		2020
Segment Adjusted EBITDA for reportable segments	$	(40,042)	$	(38,856)	$	(31,374)
All Other Segment Adjusted EBITDA			—		—
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,362		2,483		605
Add recognition of previously deferred revenue associated with upfront and milestone payments	16,007		2,034		25,005
Other expenses:
Interest expense	(6,774)		(18,755)		(18,209)
Depreciation and amortization	(7,191)		(8,139)		(8,292)
Loss from disposals of assets			(53)		(50)
Impairment losses	(1,120)		(543)		(814)


Stock-based compensation expense	(10,197)		(13,554)		(19,008)
Adjustment related to accrued bonuses paid in equity awards	1,698		—		2,833
Equity in net loss of affiliates	861		(3)		(603)
Other	(105)		(19)		11
Unallocated corporate costs	(32,913)		(33,506)		(48,915)
Eliminations	(1,552)		(2,056)		(5,713)
Consolidated loss from continuing operations before income taxes	$	(79,966)	$	(110,967)	$	(104,524)

Reconciliation of Revenue from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Year Ended December 31,
	2022		2021		2020
Total segment revenues from reportable segments	$	28,355	$	15,904	$	36,735
Other revenues, including from other operating segments	—		—		54
Elimination of intersegment revenues	(1,446)		(1,637)		(4,797)
Total consolidated revenues	$	26,909	$	14,267	$	31,992

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2022:


	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2022
Assets
United States government debt securities	$	—	$	50,995	$	—	$	50,995

Certificates of deposit	—		97		—		97
Total	$	—	$	51,092	$	—	$	51,092

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021:


	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2021
Assets
United States government debt securities	$	—	$	120,705	$	—	$	120,705

Certificates of deposit	—		97		—		97
Total	$	—	$	120,802	$	—	$	120,802

Investments in Joint Ventures	12 Months Ended
Investments in Joint Ventures	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, a JV formed to optimize and scale-up the Company's MBP technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. Intrexon Energy Partners was governed by the Intrexon Energy Partners Board, which has five members. Prior to Precigen’s purchase of certain membership interests from the IEP Investors in the third quarter of 2022 as discussed below and in Note 3, two members of the Intrexon Energy Partners Board were designated by the Company and three members were designated by a majority of the IEP Investors. Upon accumulating 87.5% of the membership interests owned by the IEP Investors in the third quarter of 2022, the Company obtained the right to designate all members of the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(428) as of December 31, 2021, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners. See Notes 3 for additional discussion regarding the Company's investment in Intrexon Energy Partners. Intrexon Energy Partners II In 2015, the Company and certain investors (the "IEPII Investors"), including Harvest Intrexon Enterprise Fund I, LP ("Harvest"), entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, a JV formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. Also in 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II was governed by the Intrexon Energy Partners II Board, which has five members. Prior to Precigen’s purchase of the membership interests from the IEPII Investors in the third quarter of 2022, one member of the Intrexon Energy Partners II Board was designated by the Company and four members were designated by a majority of the IEPII Investors. Upon acquisition of all of the membership interests owned by the IEPII Investors in the third quarter of 2022 (the Company purchased the remaining 2.9% membership units in the fourth quarter of 2022), the Company obtained the right to designate all members of the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(435) as of December 31, 2021, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II. See Notes 5for additional discussion regarding the Company's investment in Intrexon Energy Partners II. Acquisition of Membership Interests in Intrexon Energy Partners and Intrexon Energy Partners II On December 29, 2021, the Company received a letter from a group of investors in each of Intrexon Energy Partners and Intrexon Energy Partners II, referring certain issues to arbitration pursuant to the arbitration provisions of the Amended and Restated Limited Liability Company Agreements of Intrexon Energy Partners and Intrexon Energy Partners II (the “Arbitration Matters”). In July 2022, the arbitration panel ruled on the Arbitration Matters, and adopted the Company’s proposed terms with respect to each of the Arbitration Matters and, pursuant to that ruling, the Company acquired the membership interests of the investors for an aggregate amount of approximately $7,000 in cash. The Company recorded the $7,000 payment as a reduction of the revenue in 2022 (from deferred revenue – see Note 5) upon the Company obtaining control of Intrexon Energy Partners and Intrexon Energy Partners II. The fair value of the net assets of Intrexon Energy Partners and Intrexon Energy Partners II at the acquisition date is deemed to be substantially $0. The Company liquidated and dissolved Intrexon Energy Partners and Intrexon Energy Partners II during the fourth quarter of 2022, which did not have a material impact on the financial statements of the Company.

Investments in Joint Ventures - Interests in Intrexon Energy Partners and Intrexon Energy Partners II (Details)	1 Months Ended
	Jul. 31, 2022 USD ($)
Intrexon Energy Partners And Interxon Energy Partners II
Schedule of Equity Method Investments [Line Items]
Fair value, net asset (liability)	$ 0
Intrexon Energy Partners And Interxon Energy Partners II
Schedule of Equity Method Investments [Line Items]
Capital contribution	$ 7,000,000

Income Taxes - Components of Income Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
United States federal income taxes:
Deferred	$ 37	$ 37	$ 37
Foreign income taxes:
Current	(39)	7	74
Deferred	(198)	(215)	(204)
State income taxes:
Deferred	11	11	11
Total income tax benefit from continuing operations	$ (189)	$ (160)	$ (82)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Operating Leases - Additional Information (Details)	12 Months Ended
Operating Leases - Additional Information (Details)	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	8 years

Segments - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
Segments - Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill
Beginning of year	$ 37,554
Foreign currency translation adjustments	(149)	$ (215)
Impairment of goodwill	(482)	0	$ (9,635)
End of year	36,923	37,554
Operating segments
Goodwill
Beginning of year		37,769
End of year			37,769
Operating segments \| Biopharmaceuticals
Goodwill
Beginning of year	17,478	17,693
Foreign currency translation adjustments	(149)	(215)
Impairment of goodwill	(482)
End of year	16,847	17,478	17,693
Operating segments \| Exemplar
Goodwill
Beginning of year	20,076	20,076
Foreign currency translation adjustments	0	0
Impairment of goodwill	0
End of year	$ 20,076	$ 20,076	$ 20,076

- Definition

+ References + Details

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,393	$ 2,866	$ 3,049
Impairment of long-lived assets held-for-use	$ 638	$ 543	$ 814
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	Impairment of other noncurrent assets	Impairment of other noncurrent assets

Segments - Revenues by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenues from external customers	$ 26,909	$ 14,267	$ 31,992
Total segment revenues from reportable segments
Segment Reporting Information [Line Items]
Revenues	28,355	15,904	36,735
Operating segments
Segment Reporting Information [Line Items]
Revenues from external customers	26,909	14,267	31,938
Revenues	28,355	15,904	36,735
Operating segments \| Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues from external customers	14,894	922	21,780
Revenues	16,340	2,559	26,577
Operating segments \| Exemplar
Segment Reporting Information [Line Items]
Revenues from external customers	12,015	13,345	10,158
Revenues	12,015	13,345	10,158
Intersegment revenues
Segment Reporting Information [Line Items]
Revenues	1,446	1,637	4,797
Intersegment revenues \| Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues	1,446	1,637	4,797
Intersegment revenues \| Exemplar
Segment Reporting Information [Line Items]
Revenues	0	0	0
Other revenues, including from other operating segments
Segment Reporting Information [Line Items]
Revenues	0	0	54
Elimination of intersegment revenues
Segment Reporting Information [Line Items]
Revenues	$ (1,446)	$ (1,637)	$ (4,797)

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Federal and state research and development tax credits	$ 12,160	$ 11,168
Accumulated deficit	1,868,567	$ 1,915,556
Foreign Subsidiaries
Operating Loss Carryforwards [Line Items]
Accumulated deficit	26,184
Domestic
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition	41,400
Operating loss carryforwards	819,100
Deferred tax assets, capital loss carryforwards	212,500
Federal and state research and development tax credits	12,100
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	71,000
Generated after 2017 \| Domestic
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 604,200

Defined Contribution Plans	12 Months Ended
Defined Contribution Plans	Dec. 31, 2022
Retirement Benefits [Abstract]
Defined Contribution Plans	Defined Contribution PlansThe Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $564, $388, and $397 for the years ended December 31, 2022, 2021, and 2020, respectively.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Components of Loss Before Income Taxes

The components of loss from continuing operations before income taxes are presented below:


	Year Ended December 31,
	2022		2021		2020
Domestic	$	(76,572)	$	(107,582)	$	(97,982)
Foreign	(3,394)		(3,385)		(6,542)
Loss from continuing operations before income taxes	$	(79,966)	$	(110,967)	$	(104,524)

Components of Income Tax Benefit

The components of income tax benefit from continuing operations are presented below:


	Year Ended December 31,
	2022		2021		2020
United States federal income taxes:

Deferred	$	37	$	37	$	37
Foreign income taxes:
Current	(39)		7		74
Deferred	(198)		(215)		(204)
State income taxes:

Deferred	11		11		11
Income tax benefit from continuing operations	$	(189)	$	(160)	$	(82)

Schedule of Effective Income Tax Rate Reconciliation


	2022		2021		2020
Computed statutory income tax benefit from continuing operations	$	(16,793)	$	(23,303)	$	(21,950)
State and provincial income tax benefit, net of federal income taxes	(2,884)		(4,670)		(5,199)
Nondeductible stock based compensation	179		832		5,709
Nondeductible officer compensation	263		1,459		728
Impairment of goodwill	101		—		—
Nondeductible equity investment loss	3,093		—		—
Research and development tax incentives	(991)		(958)		(524)
Acquisition and internal restructuring transaction costs	—		—		—



United States-foreign rate differential	18		(32)		(21)
Other, net	533		(46)		(306)
	(16,481)		(26,718)		(21,563)
Change in valuation allowance for deferred tax assets	16,292		26,558		21,481
Total income tax benefit from continuing operations	$	(189)	$	(160)	$	(82)

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December 31, 2022 and 2021, are as follows:


	2022		2021
Deferred tax assets
Allowance for doubtful accounts	$	53	$	1,506
Inventory	—		370
Equity securities and investments in affiliates	258		570
Property, plant and equipment	284		—
Intangible assets	69,807		80,540
Accrued liabilities	3,219		3,090
Lease liabilities	2,182		2,839
Stock-based compensation	17,106		15,227
Deferred revenue	474		7,300
Capitalized research and development cost	16,318		—
Research and development tax credits	12,160		11,168

Net operating, capital loss, and interest expense carryforwards	288,397		301,791
Total deferred tax assets	410,258		424,401
Less: (Valuation allowance)	401,086		408,396
Net deferred tax assets	9,172		16,005
Deferred tax liabilities
Property, plant and equipment	—		250
Right-of-use assets	2,071		2,735

Foreign intangible asset	9,364		10,861
Long-term debt	—		4,698
Total deferred tax liabilities	11,435		18,544
Net deferred tax liabilities included in continuing operations	$	(2,263)	$	(2,539)

Summary of Valuation Allowance

Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December 31, 2022, 2021, and 2020 was as follows:


	2022		2021		2020
Valuation allowance at beginning of year	$	408,396	$	387,348	$	349,008
Increase (decrease) in valuation allowance as a result of

Deconsolidation of AquaBounty	—		—		—
Establishment of deferred taxes for subsidiaries included in discontinued operations	—		—		—
Current year continuing operations	16,292		26,558		21,481
Discontinued operations treated as asset sales	(27,909)		(3,626)		7,805
Discontinued operations related to MBP Titan	—		(1,186)		8,019





Adoption of ASU 2020-06	4,698		—		—
Foreign currency translation adjustment	(391)		(698)		1,035
Valuation allowance at end of year	$	401,086	$	408,396	$	387,348

Discontinued Operations - Summary of Financial Results for Trans Ova (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations	$ 108,094	$ 18,641	$ (66,079)
Trans Ova \| Discontinued Operations, Held-for-sale or Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	71,151	89,606	71,186
Cost of products	18,634	23,070	26,529
Cost of services	22,701	29,570	23,610
Research and development	2,348	2,208	2,216
Selling, general and administrative	15,215	22,128	19,010
Impairment of assets	0	0	106
Total operating expenses	58,898	76,976	71,471
Operating income (loss)	12,253	12,630	(285)
Other income, net	1,139	1,412	1,489
Equity in net loss of affiliates	0	0	(535)
Gain on sale of discontinued operations	94,702	0	0
Income (loss) before income taxes	108,094	14,042	669
Income tax expense	0	0	0
Income from discontinued operations	108,094	14,042	669
Trans Ova \| Discontinued Operations, Held-for-sale or Disposed of by Sale \| Product revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	21,494	25,131	21,914
Trans Ova \| Discontinued Operations, Held-for-sale or Disposed of by Sale \| Service revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	$ 49,657	$ 64,475	$ 49,272

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Cumulative effect of adoption of ASU 2020-06	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative effect of adoption of ASU 2020-06	Accumulated Other Comprehensive Income	Accumulated Deficit	Accumulated Deficit Cumulative effect of adoption of ASU 2020-06
Beginning balance at Dec. 31, 2019	$ 71,711		$ 0	$ 1,752,048		$ (27,468)	$ (1,652,869)
Beginning balance, shares at Dec. 31, 2019			163,274,880
Changes in Stockholders' Equity
Stock-based compensation expense	18,366			18,366
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	117			117
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares			877,249
Shares issued for accrued compensation	5,100			5,100
Shares issued for accrued compensation, shares			1,955,405
Shares issued as payment for services	1,006			1,006
Shares issued as payment for services, shares			413,911
Shares issued in private placement	35,000			35,000
Shares issued in private placement, shares			5,972,696
Shares issued upon conversion of long-term debt	56,827			56,827
Shares issued upon conversion of long-term debt, shares			13,051,802
Shares issued in conjunction with settlement agreement	18,103			18,103
Stock issued in conjunction with settlement agreement, shares			2,117,264
Net loss	(170,521)						(170,521)
Release of cumulative translation adjustment to loss from discontinued operations	26,957					26,957
Other comprehensive income (loss)	4,508					4,508
Ending balance at Dec. 31, 2020	$ 67,174		$ 0	1,886,567		3,997	(1,823,390)
Ending balance, shares at Dec. 31, 2020			187,663,207
Changes in Stockholders' Equity
Cumulative effect of adoption of ASC 606 [Extensible List]	Adoption of ASU 2020-06
Stock-based compensation expense	$ 13,904			13,904
Shares issued upon vesting of restricted stock units and for exercises of stock options	608			608
Shares issued upon vesting of restricted stock units and for exercises of stock options, shares			1,751,896
Shares issued as payment for services	577			577
Shares issued as payment for services, shares			74,771
Shares issued in private placement	121,045			121,045
Shares issued in private placement, shares			17,250,000
Net loss	(92,166)						(92,166)
Release of cumulative translation adjustment to loss from discontinued operations	0
Other comprehensive income (loss)	(3,794)					(3,794)
Ending balance at Dec. 31, 2021	$ 107,348	$ (18,196)	$ 0	2,022,701	$ (36,868)	203	(1,915,556)	$ 18,672
Ending balance, shares at Dec. 31, 2021	206,739,874		206,739,874
Changes in Stockholders' Equity
Stock-based compensation expense	$ 10,207			10,207
Shares issued upon vesting of restricted stock units and for exercises of stock options	1			1
Shares issued upon vesting of restricted stock units and for exercises of stock options, shares			354,089
Shares issued for accrued compensation	1,698			1,698
Shares issued for accrued compensation, shares			772,071
Shares issued as payment for services	575			575
Shares issued as payment for services, shares			283,987
Net loss	28,317						28,317
Release of cumulative translation adjustment to loss from discontinued operations	0
Other comprehensive income (loss)	(3,691)					(3,691)
Ending balance at Dec. 31, 2022	$ 126,259		$ 0	$ 1,998,314		$ (3,488)	$ (1,868,567)
Ending balance, shares at Dec. 31, 2022	208,150,021		208,150,021

Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Total accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ (3,488)	$ 203
Unrealized gain (loss) on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	(760)	(331)
Income (loss) on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ (2,728)	$ 534

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

+ Details

Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease costs	$ 2,444	$ 2,872	$ 3,239
Short-term lease costs	170	252	311
Variable lease costs	422	800	842
Lease costs	$ 3,036	$ 3,924	$ 4,392

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 164	$ 164
Buildings and building improvements	2,592	2,592
Furniture and fixtures	457	434
Equipment	18,006	16,812
Leasehold improvements	4,333	3,366
Breeding stock	123	36
Computer hardware and software	4,562	4,823
Construction and other assets in progress	531	1,829
Property, plant and equipment, gross	30,768	30,056
Less: Accumulated depreciation and amortization	(23,439)	(21,457)
Property, plant and equipment, net	$ 7,329	$ 8,599

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ (40,042)	$ (38,856)	$ (31,374)
Other expenses:
Depreciation and amortization	(10,765)	(13,761)	(17,516)
Stock-based compensation expense	(10,206)	(13,904)	(18,366)
Equity in net income (loss) of affiliates	862	(3)	(1,176)
Other	(106)	(24)	(35)
Loss before income taxes	(79,966)	(110,967)	(104,524)
Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	14,561	397	20,205
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,362	2,483	605
Operating segments \| Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	16,007	2,034	25,005
Corporate And Reconciling Items
Other expenses:
Interest expense	(6,774)	(18,755)	(18,209)
Depreciation and amortization	(7,191)	(8,139)	(8,292)
Loss from disposals of assets		(53)	(50)
Impairment losses	(1,120)	(543)	(814)
Stock-based compensation expense	(10,197)	(13,554)	(19,008)
Adjustment related to accrued bonuses paid in equity awards	1,698	0	2,833
Equity in net income (loss) of affiliates	861	(3)	(603)
Other	(105)	(19)	11
Unallocated corporate costs
Other expenses:
Loss before income taxes	(32,913)	(33,506)	(48,915)
Eliminations
Other expenses:
Loss before income taxes	(1,552)	(2,056)	(5,713)
Segment Adjusted EBITDA for reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	(40,042)	(38,856)	(31,374)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments		$ 0	$ 0

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2020
Related Party Transaction [Line Items]
Shares issued in conjunction with settlement agreement					$ 18,103
Deferred revenue			$ 1,843	$ 24,513
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc.
Related Party Transaction [Line Items]
Investments in affiliates						$ 326
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Deferred revenue			1,818	23,023
Harvest Intrexon Enterprise Fund I, LP
Related Party Transaction [Line Items]
Stock issued in conjunction with settlement agreement, shares		2,117,264
Shares issued in conjunction with settlement agreement		$ 18,103
Loss related to litigation settlement		11,436
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. \| Collaboration and licensing agreements
Related Party Transaction [Line Items]
Deferred revenue		$ 6,993			6,993
Third Security
Related Party Transaction [Line Items]
Expense for services			25	100	159
Sublease rental income			$ 0	$ 75	$ 83
Cash received on contract termination	$ 143
Third Security \| Executive Chairman
Related Party Transaction [Line Items]
Ownership interest			100.00%

Segments

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segments

SegmentsThe Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where

noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net loss of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates but includes proceeds from the sale of assets in the period sold. Segment Adjusted EBITDA excludes the gain or loss on disposals of assets and include proceeds from the sale of assets in the period sold.

Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the businesses included in the Transactions, the operations of MBP Titan and Trans Ova which are reported as discontinued operations (Note 3).

For the year ended December 31, 2022, the Company's reportable segments were (i) Biopharmaceuticals and (ii) Exemplar. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December 31, 2022. See Note 2 for a description of Biopharmaceuticals and Exemplar.

Segment Adjusted EBITDA by reportable segment was as follows:


	Year Ended December 31,
	2022		2021		2020
Biopharmaceuticals	$	(45,039)	$	(45,754)	$	(35,378)
Exemplar	4,997		6,898		4,004


Segment Adjusted EBITDA for operating segments	$	(40,042)	$	(38,856)	$	(31,374)

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Year Ended December 31,
	2022		2021		2020
Segment Adjusted EBITDA for reportable segments	$	(40,042)	$	(38,856)	$	(31,374)
All Other Segment Adjusted EBITDA			—		—
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,362		2,483		605
Add recognition of previously deferred revenue associated with upfront and milestone payments	16,007		2,034		25,005
Other expenses:
Interest expense	(6,774)		(18,755)		(18,209)
Depreciation and amortization	(7,191)		(8,139)		(8,292)
Loss from disposals of assets			(53)		(50)
Impairment losses	(1,120)		(543)		(814)


Stock-based compensation expense	(10,197)		(13,554)		(19,008)
Adjustment related to accrued bonuses paid in equity awards	1,698		—		2,833
Equity in net loss of affiliates	861		(3)		(603)
Other	(105)		(19)		11
Unallocated corporate costs	(32,913)		(33,506)		(48,915)
Eliminations	(1,552)		(2,056)		(5,713)
Consolidated loss from continuing operations before income taxes	$	(79,966)	$	(110,967)	$	(104,524)

Revenues by reportable segment were as follows:


	Year Ended December 31, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	14,894	$	12,015	$	26,909
Intersegment revenues	1,446		—		1,446
Total segment revenues	$	16,340	$	12,015	$	28,355


	Year Ended December 31, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	922	$	13,345	$	14,267
Intersegment revenues	1,637		—		1,637
Total segment revenues	$	2,559	$	13,345	$	15,904


	Year Ended December 31, 2020
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	21,780	$	10,158	$	31,938
Intersegment revenues	4,797		—		4,797
Total segment revenues	$	26,577	$	10,158	$	36,735

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Year Ended December 31,
	2022		2021		2020
Total segment revenues from reportable segments	$	28,355	$	15,904	$	36,735
Other revenues, including from other operating segments	—		—		54
Elimination of intersegment revenues	(1,446)		(1,637)		(4,797)
Total consolidated revenues	$	26,909	$	14,267	$	31,992

For the years ended December 31, 2022, 2021, and 2020, 59.6%, 61.5%, and 51.9% of total Exemplar segment revenue was attributable to one customer, respectively. The Company recognized revenues derived in foreign countries totaling $233, $378, and $595 for the years ended December 31, 2022, 2021, and 2020, respectively.

Goodwill by reportable segment was as follows:


	Biopharmaceuticals		Exemplar		Total
Goodwill
Balances at December 31, 2020	$	17,693	$	20,076	$	37,769


Foreign currency translation adjustments	(215)		—		(215)
Balances at December 31, 2021	17,478		20,076		37,554


Foreign currency translation adjustments	(149)		—		(149)
Impairments	(482)		—		(482)
Balances at December 31, 2022	$	16,847	$	20,076	$	36,923

As of December 31, 2022 and 2021, the Company had $2,591 and $4,463, respectively, of long-lived assets in foreign countries.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 43,219	$ 179,934
Less current portion	43,219	52
Long-term debt, less current portion	0	179,882
Convertible debt
Debt Instrument [Line Items]
Long-term debt	43,219	179,882
Other
Debt Instrument [Line Items]
Long-term debt	$ 0	$ 52

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details) - Precigen Stock Option Plans	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, minimum	87.00%	87.00%	59.00%
Expected volatility, maximum	89.00%	90.00%	90.00%
Expected term (years)	6 years 3 months	6 years
Risk-free interest rate, minimum	1.64%	0.61%	0.36%
Risk-free interest rate, maximum	4.12%	1.33%	1.80%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	10 years

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2022

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations

The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale related to Trans Ova as of December 31, 2021 are as follows:


	December 31,
	2021

Assets
Cash and cash equivalents	$	6,497
Trade Receivables, net	19,491
Inventory	12,935
Other current assets	1,265
Property, plan and equipment, net	25,716
Intangible assets, net	1,824
Goodwill	16,594
Right-of-use assets	910
Other noncurrent assets	252
Total assets held for sale	$	85,484
Liabilities
Accounts payable	$	2,293
Accrued compensation and benefits	3,367
Other accrued liabilities	3,778
Deferred revenue	2,952

Current portion of long-term debt	350
Other current liabilities	111
Long-term debt, net of current portion	2,867

Other long-term liabilities	805
Total liabilities held for sale or abandonment	$	16,523

The following table presents the financial results of discontinued operations related to TransOva through the date of disposition in 2022:


	Year Ended December 31,
	2022		2021		2020
Product revenues	$	21,494	$	25,131	$	21,914
Service revenues	49,657		64,475		49,272
Total revenues	71,151		89,606		71,186
Cost of products	18,634		23,070		26,529
Cost of services	22,701		29,570		23,610
Research and development	2,348		2,208		2,216
Selling, general and administrative	15,215		22,128		19,010
Impairment of assets	—		—		106
Total operating expenses	58,898		76,976		71,471
Operating income (loss)	12,253		12,630		(285)
Other income, net	1,139		1,412		1,489
Equity in net loss of affiliates	—		—		(535)
Gain on divestiture	94,702		—		—
Income before income taxes	$	108,094	$	14,042	$	669
Income tax (expense) benefit	—		—		—
Income from discontinued operations	$	108,094	$	14,042	$	669


	Year Ended December 31,
	2022	2021	2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	3,574	5,622	6,750

Impairment of assets	—	—	106
Loss on disposal of assets	421	561	4,325
Equity in net loss of affiliates	—	—	535


Provision for credit losses	944	1,128	899
Stock-based compensation expense	9	350	738


Cash flows from investing activities
Proceeds from repayment of notes receivable	—	3,689	—
Purchases of property, plant and equipment	(3,529)	(4,694)	(6,365)
Proceeds from sales of assets	594	1,894	2,387

The following table presents the financial results of discontinued operations related to MBP Titan:


	Year Ended December 31,
		2021		2020

Operating (gains) expenses (1)		$	(4,599)	$	40,692
Operating income (loss)		4,599		(40,692)




Income (loss) before income taxes		4,599		(40,692)

Income (loss) from discontinued operations		$	4,599	$	(40,692)

The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan that are included in the accompanying consolidated statements of cash flows.


	Year Ended December 31,
	2021		2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	—	2,474
Impairment of goodwill	—		9,635
Impairment of other noncurrent assets	—		12,406
(Gain) loss on disposal of assets, net	(464)		67




Stock-based compensation expense	—		(34)

Noncash gain on termination of leases	(4,602)		—
Cash flows from investing activities

Purchases of property, plant and equipment	—		(88)
Proceeds from sales of assets	1,083		3,952

The following tables present the financial results of discontinued operations related to the Transactions for the year ended December 31, 2020.


	Year Ended December 31, 2020
	TS Biotechnology Sale		EnviroFlight Sale		Total
Revenues (1)	$	1,294	$	—	$	1,294
Operating expenses	896		—		896
Operating income	398		—		398
Gain on sale of discontinued operations	633		39		672
Loss on release of cumulative foreign currency translation adjustment	(26,957)		—		(26,957)
Other expense, net	(129)		—		(129)
Equity in net loss of affiliates	—		(38)		(38)
Income (loss) before income taxes	(26,055)		1		(26,054)
Income tax expense	(2)		—		(2)
Income (loss) from discontinued operations	$	(26,057)	$	1	$	(26,056)

(1)Includes revenue recognized from related parties of $436.


	Year Ended December 31,
	2020
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	—
Impairment of goodwill	—
Impairment of other noncurrent assets	—
Gain on sale of discontinued operations	(672)
Loss on release of cumulative foreign currency translation adjustment	26,957
Unrealized and realized depreciation on equity securities and preferred stock, net	106
Equity in net loss of EnviroFlight	38
Stock-based compensation expense	(1,346)
Deferred income taxes	—
Cash flows from investing activities
Investments in EnviroFlight	—
Purchases of property, plant and equipment	(382)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 51,092	$ 120,802
United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	50,995	120,705
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	97	97
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Quoted Prices in Active Markets (Level 1) \| United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Quoted Prices in Active Markets (Level 1) \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	51,092	120,802
Significant Other Observable Inputs (Level 2) \| United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	50,995	120,705
Significant Other Observable Inputs (Level 2) \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	97	97
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Significant Unobservable Inputs (Level 3) \| United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Significant Unobservable Inputs (Level 3) \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 0	$ 0

Property, Plant and Equipment, Net

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:


	December 31,
	2022		2021
Land and land improvements	$	164	$	164
Buildings and building improvements	2,592		2,592
Furniture and fixtures	457		434
Equipment	18,006		16,812
Leasehold improvements	4,333		3,366
Breeding stock	123		36
Computer hardware and software	4,562		4,823

Construction and other assets in progress	531		1,829
	30,768		30,056
Less: Accumulated depreciation and amortization	(23,439)		(21,457)
Property, plant and equipment, net	$	7,329	$	8,599

Depreciation expense was $2,393, $2,866, and $3,049 for the years ended December 31, 2022, 2021, and 2020, respectively.

Recorded impairment losses of $638, $543 and $814 for the years ended December 31, 2022, 2021, and 2020, respectively, are included in impairment of other noncurrent assets on the accompanying consolidated statement of operations and are primarily related to right-of-use assets at certain of the Company's leased locations.

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Deloitte & Touche LLP
Auditor Location	Baltimore, Maryland
Auditor Firm ID	34

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 51,852	$ 121,133
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(760)	(331)
Aggregate Fair Value	51,092	120,802
Revenues	26,909	14,267	$ 31,992
United States government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	51,755	121,036
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(760)	(331)
Aggregate Fair Value	50,995	120,705
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	97	97
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 97	$ 97

- Definition

+ References

+ Details

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	$ 82,692	$ 86,973
Accumulated Amortization	(38,237)	(34,682)
Finite-lived intangible assets, net, total	44,455	52,291
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	80,892	85,173
Accumulated Amortization	(36,437)	(32,882)
Finite-lived intangible assets, net, total	44,455	52,291
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	1,600	1,600
Accumulated Amortization	(1,600)	(1,600)
Finite-lived intangible assets, net, total	0	0
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	200	200
Accumulated Amortization	(200)	(200)
Finite-lived intangible assets, net, total	$ 0	$ 0
Weighted Average Useful Life (Years) \| Patents, developed technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	16 years 4 months 24 days
Weighted Average Useful Life (Years) \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	3 years
Weighted Average Useful Life (Years) \| Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	5 years

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Accounts Receivable, Allowance for Credit Losses

The following table shows the activity in the allowance for credit losses for the years ended December 31, 2022, 2021, and 2020:


	2022		2021		2020
Beginning balance	$	1,693	$	1,509	$	2,312
Charged to operating expenses	—		140		—
Write offs of accounts receivable, net of recoveries	(1,509)		44		(803)
Ending balance	184		1,693		1,509

Estimated Useful Lives of Property, Plant and Equipment

The estimated useful lives of these assets from continuing operations are as follows:


			Years
Land improvements			9–15
Buildings and building improvements			9–15
Furniture and fixtures			4–7
Equipment			2–7
Breeding stock			2
Computer hardware and software			1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to eleven years.

Summary of Assumptions Used in Option Pricing Model

The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022, 2021, and 2020 are set forth in the table below:


	2022	2021	2020
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	87%–89%	87%–90%	59%–90%
Expected term (years)	6.25	6.00	6.00-10.00
Risk-free interest rate	1.64%–4.12%	0.61%–1.33%	0.36%–1.80%

Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share

The following potentially dilutive securities as of December 31, 2022, 2021, and 2020, have been excluded from the computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:


	December 31,
	2022	2021	2020

Options	15,201,276	12,260,187	11,255,896
Restricted stock units	697,815	468,481	1,727,712
Warrants	—	121,888	133,264
Total	15,899,091	12,850,556	13,116,872

Collaboration and Licensing Revenue - Additional Information (Details)	1 Months Ended					12 Months Ended							24 Months Ended
	Jul. 31, 2022 USD ($)	Jul. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Feb. 29, 2020 USD ($)	Oct. 31, 2012 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) product	Dec. 31, 2015 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2016 USD ($)
Collaboration Agreements [Line Items]
Revenues						$ 26,909,000	$ 14,267,000	$ 31,992,000
Deferred revenue						1,843,000	24,513,000
Long-term portion of deferred revenue						1,818,000	23,023,000
Intrexon Energy Partners And Interxon Energy Partners II
Collaboration Agreements [Line Items]
Capital contribution	$ 7,000,000
Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible										20.00%
License agreement, percentage of operating profits to be received										20.00%
License agreement, annual fee										$ 100,000
License agreement, reimbursement of historical costs									$ 1,000,000
Milestone payments required upon successful achievement, aggregated										210,000,000
License agreement, royalty due, aggregated										$ 100,000,000
License agreement, percentage of sublicensing income										20.00%
Transition period during which costs will be reimbursed										1 year
License agreement, termination, period following triggering event										12 years
Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues	$ 14,561,000					14,661,000	506,000	21,208,000
Deferred revenue						1,818,000	23,023,000
Maximum \| Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product										$ 52,500,000
License agreement, number of exclusively licensed products \| product										4
Alaunos Therapeutics, Inc. \| Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible										80.00%
License agreement, percentage of operating profits to be received										80.00%
License agreement, royalty due, aggregated										$ 50,000,000
Alaunos Therapeutics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues						100,000	100,000	200,000
Deferred revenue										$ 1,855,000
Oragenics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues						0	0	3,053,000
Collaborative agreement, consideration received, value of convertible promissory note											$ 5,000,000
Revenue recognized from previously deferred balances		$ 2,823,000
Castle Creek Biosciences, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues						0	388,000	17,810,000
Revenue recognized from previously deferred balances				$ 10,000,000
Collaborative agreement, consideration received, value					$ 7,576,000							$ 7,612,000
Collaborative agreement, consideration received, cash									$ 3,750,000
Royalty rate as a percentage of net sales, tier 1			7.00%
Level of net sales at which royalty rate changes to tier 2			$ 25,000,000
Royalty rate as a percentage of net sales, tier 2			14.00%
Intrexon Energy Partners L.L. and Intrexon Energy Partners II, L.L.C
Collaboration Agreements [Line Items]
Long-term portion of deferred revenue						$ 0	$ 21,205,000
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue								$ 6,993,000
Collaborative agreement, consideration received, value													$ 11,000,000

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Minimum \| Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	9 years
Minimum \| Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	9 years
Minimum \| Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Minimum \| Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	2 years
Minimum \| Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Maximum \| Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	15 years
Maximum \| Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	15 years
Maximum \| Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum \| Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum \| Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum \| Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	11 years

Goodwill and Intangible Assets, Net

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021, are as follows:


	2022		2021
Beginning of year	$	37,554	$	37,769

Impairment	(482)		—
Foreign currency translation adjustments	(149)		(215)
End of year	$	36,923	$	37,554

The Company had $14,483 and $14,001 of cumulative goodwill impairment losses as of December 31, 2022 and 2021,

The Company recorded $482 of goodwill impairment related to the total goodwill assigned to one reporting unit within the biopharmaceutical segment during the year ended December 31, 2022.

See Note 18 for information regarding goodwill by reportable segment.

Intangible assets consist of the following as of December 31, 2022:


	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net
Patents, developed technologies and know-how	16.4	$	80,892	$	(36,437)	$	44,455
Customer relationships	3.0	1,600		(1,600)		—
Trademarks	5.0	200		(200)		—

Total		$	82,692	$	(38,237)	$	44,455

Intangible assets consist of the following as of December 31, 2021:


	Gross Carrying Amount		Accumulated Amortization		Net
Patents, developed technologies and know-how	$	85,173	$	(32,882)	$	52,291
Customer relationships	1,600		(1,600)		—
Trademarks	200		(200)		—

Total	$	86,973	$	(34,682)	$	52,291

Amortization expense was $4,798, $5,273, and $5,243 for the years ended December 31, 2022, 2021, and 2020, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:


2023	$	4,773
2024	4,773
2025	4,773
2026	4,773
2027	4,773
Thereafter	20,590
Total	$	44,455

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Components of Lease Costs

The components of lease costs were as follows:


	Year Ended December 31,
	2022		2021		2020
Operating lease costs	$	2,444	$	2,872	$	3,239
Short-term lease costs	170		252		311
Variable lease costs	422		800		842
Lease costs	$	3,036	$	3,924	$	4,392

Other information related to operating leases in continuing operations was as follows:


	December 31,
	2022		2021
Weighted average remaining lease term (years)	6.09		6.72
Weighted average discount rate	11.05	%	10.94	%


	Year Ended December 31,
	2022		2021		2020
Supplemental disclosure of cash flow information
Cash paid for operating lease liabilities	$	2,493	$	3,199	$	3,679
Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases)	466		4,868		112

Maturities of Lease Liabilities

As of December 31, 2022, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:


2023	$	2,074
2024	1,882
2025	1,851
2026	1,508
2027	1,246
Thereafter	3,108
Total	11,669
Present value adjustment	(3,468)
Total	$	8,201
Current portion of operating lease liabilities	$	1,209
Long-term portion of operating lease liabilities	6,992
Total	$	8,201

Lines of Credit and Long-Term Debt - Components of Interest Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Non-cash interest expense	$ 11,800
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Cash interest expense	5,727	$ 7,000	$ 7,000
Non-cash interest expense	1,042	11,735	10,587
Total interest expense	$ 6,769	$ 18,735	$ 17,587

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns 100% of the equity interests of Third Security. Through December 2019, the Company was party to a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. Following the expiration of the Services Agreement, the Company entered into a new agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company which expired on December 31, 2021. As the Company evaluated its alternatives, it continued to utilize these services on a limited basis under the terms of the original agreement. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf prior to and after the expiration of the Services Agreement under a separate agreement. The total expenses incurred by the Company under these arrangements were $25, $100, and $159 for the years ended December 31, 2022, 2021, and 2020, respectively. See also Note 14 regarding compensation arrangements between the Company and its Executive Chairman. Through November 2021, the Company also subleased certain administrative offices to Third Security. The significant terms of the lease mirrored the terms of the Company's lease with the landlord, and the Company recorded sublease income of $0, $75, and $83 for the years ended December 31, 2022, 2021, and 2020, respectively. During November 2021, in conjunction with the early termination of the sublease, Third Security paid the Company $143 which represented a pro rata portion of the early termination fee the Company paid the landlord. See Notes 1, 3, and 13 regarding additional transactions with affiliates of Third Security. Other Related Parties In December 2020, the Company entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and to settle all claims made in connection with the notice of arbitration noted above. Pursuant to the settlement agreement, the Company issued 2,117,264 shares of its common stock to Harvest valued at $18,103 in consideration of (i) the termination of the ECC agreements with Thrive Agrobiotics, Exotech Bio, and AD Skincare, which the Company had $6,993 of deferred revenue remaining related to these ECCs prior to the settlement agreement; (ii) the return of the Company's ownership interest in these Harvest start-up entities that had a total value of $326 prior to the settlement agreement; (iii) the commitment of Harvest (which is still ongoing) to take reasonable commercial efforts to transfer to the Company its membership interests in Intrexon Energy Partners II; and (iv) mutual irrevocable and unconditional releases of claims. The Company wrote off the investment balances and netted the deferred revenue balances associated with the eliminated service obligation against the consideration paid, resulting in a loss on the settlement agreement of $11,436, which is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2020. Outstanding receivables from these Harvest start-up entities related to research and development services performed by the Company under the ECC agreements, which had been fully reserved in 2019, were also forgiven as part of the settlement agreement and written off by the Company. Following the settlement agreement, these Harvest start-up entities are no longer related parties.

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Accounts receivable, allowance for credit loss, current	$ 184
Related party receivable, allowance for credit loss, current	0	$ 1,509
Long-term portion of deferred revenue	$ 1,818	$ 23,023
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	208,150,021	206,739,874
Common stock, shares outstanding (in shares)	208,150,021	206,739,874
Related Parties, Aggregated
Related Party Transaction [Line Items]
Long-term portion of deferred revenue	$ 0	$ 21,205

Short-term and Long-term Investments - Contractual Obligation, Fiscal year Maturity (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due within one year	$ 51,092
After one year through two years	0
Total	$ 51,092

Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	15,899,091	12,850,556	13,116,872
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	15,201,276	12,260,187	11,255,896
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	697,815	468,481	1,727,712
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	121,888	133,264

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive income (loss) are as follows:


	December 31,
	2022		2021
Unrealized gain (loss) on investments	$	(760)	$	(331)
Income (loss) on foreign currency translation adjustments	(2,728)		534
Total accumulated other comprehensive income (loss)	$	(3,488)	$	203

Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for Trans Ova (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 0	$ 6,497
Discontinued Operations, Held-for-sale or Disposed of by Sale \| Trans Ova
Assets
Cash and cash equivalents		6,497
Trade Receivables, net		19,491
Inventory		12,935
Other current assets		1,265
Property, plan and equipment, net		25,716
Intangible assets, net		1,824
Castle Creek Biosciences, Inc.		16,594
Right-of-use assets		910
Other noncurrent assets		252
Total assets held for sale		85,484
Liabilities
Accounts payable		2,293
Accrued compensation and benefits		3,367
Other accrued liabilities		3,778
Deferred revenue		2,952
Current portion of long-term debt		350
Other current liabilities		111
Long-term debt, net of current portion		2,867
Other long-term liabilities		805
Disposal Group, Including Discontinued Operation, Liabilities, Total		$ 16,523